



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

06 September 2023  
EMA/CHMP/311397/2023  
Human Medicines Division

## Committee for medicinal products for human use (CHMP)

### Minutes for the meeting on 19-22 June 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

#### Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

#### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

<b>1.</b>	<b>Introduction</b>	<b>8</b>
1.1.	<b>Welcome and declarations of interest of members, alternates and experts</b> .....	<b>8</b>
1.2.	<b>Adoption of agenda</b> .....	<b>8</b>
1.3.	<b>Adoption of the minutes</b> .....	<b>8</b>
<b>2.</b>	<b>Oral Explanations</b>	<b>9</b>
2.1.	<b>Pre-authorisation procedure oral explanations</b> .....	<b>9</b>
2.1.1.	adagrasib - EMEA/H/C/006013 .....	9
2.1.2.	gefapixant - EMEA/H/C/005884 .....	9
2.1.3.	gefapixant - EMEA/H/C/005476 .....	9
2.1.4.	natalizumab - EMEA/H/C/005752 .....	9
2.2.	<b>Re-examination procedure oral explanations</b> .....	<b>10</b>
2.2.1.	Lagevrio - molnupiravir - EMEA/H/C/005789.....	10
2.3.	<b>Post-authorisation procedure oral explanations</b> .....	<b>10</b>
2.4.	<b>Referral procedure oral explanations</b> .....	<b>10</b>
<b>3.</b>	<b>Initial applications</b>	<b>10</b>
3.1.	<b>Initial applications; Opinions</b> .....	<b>10</b>
3.1.1.	Albrioza - sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901 .....	10
3.1.2.	Aquipta - atogepant - EMEA/H/C/005871 .....	11
3.1.3.	Jesduvroq - daprodustat - EMEA/H/C/005746 .....	11
3.2.	<b>Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)</b> .....	<b>12</b>
3.2.1.	respiratory syncytial virus vaccines - EMEA/H/C/006027.....	12
3.2.2.	dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009 .....	12
3.2.3.	enalapril maleate - PUMA - EMEA/H/C/005731 .....	12
3.2.4.	latanoprost - EMEA/H/C/005933 .....	12
3.2.5.	gefapixant - EMEA/H/C/005884 .....	13
3.2.6.	gefapixant - EMEA/H/C/005476 .....	13
3.2.7.	talquetamab - PRIME - Orphan - EMEA/H/C/005864 .....	13
3.2.8.	natalizumab - EMEA/H/C/005752 .....	14
3.2.9.	fezolinetant - EMEA/H/C/005851.....	14
3.2.10.	zilucoplan - Orphan - EMEA/H/C/005450 .....	14
3.3.	<b>Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)</b> .....	<b>15</b>
3.3.1.	methylphenidate hydrochloride - PUMA - EMEA/H/C/005975 .....	15
3.3.2.	buprenorphine - EMEA/H/C/006188.....	15
3.3.3.	rdESAT-6 / rCFP-10 - EMEA/H/C/006177.....	15

3.3.4.	sugemalimab - EMEA/H/C/006088 .....	15
3.3.5.	aprocitentan - EMEA/H/C/006080 .....	16
<b>3.4.</b>	<b>Update on on-going initial applications for Centralised procedure.....</b>	<b>16</b>
3.4.1.	polihexanide - Orphan - EMEA/H/C/005858 .....	16
3.4.2.	aumolertinib - EMEA/H/C/006069 .....	16
3.4.3.	exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763 .....	16
3.4.4.	dabigatran etexilate - EMEA/H/C/006023 .....	17
3.4.5.	omecamtiv mecarbil - EMEA/H/C/006112 .....	17
3.4.6.	bevacizumab - EMEA/H/C/005723 .....	17
3.4.7.	omaveloxolone - Orphan - EMEA/H/C/006084 .....	17
<b>3.5.</b>	<b>Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 .....</b>	<b>18</b>
3.5.1.	Lagevrio - molnupiravir - EMEA/H/C/005789.....	18
<b>3.6.</b>	<b>Initial applications in the decision-making phase.....</b>	<b>18</b>
<b>3.7.</b>	<b>Withdrawals of initial marketing authorisation application .....</b>	<b>18</b>
3.7.1.	Dyrupeg - pegfilgrastim - EMEA/H/C/005810 .....	18
3.7.2.	Zefylti - filgrastim - EMEA/H/C/005888 .....	18

## **4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 19**

<b>4.1.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion .....</b>	<b>19</b>
4.1.1.	Adtralza - tralokinumab - EMEA/H/C/005255/X/0007 .....	19
4.1.2.	Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0176 .....	19
4.1.3.	Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0180 .....	19
4.1.4.	Erleada - apalutamide - EMEA/H/C/004452/X/0028/G .....	20
4.1.5.	Ofev - nintedanib - EMEA/H/C/003821/X/0052/G .....	20
4.1.6.	Tenkasi - oritavancin - EMEA/H/C/003785/X/0036.....	21
<b>4.2.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues .....</b>	<b>21</b>
4.2.1.	Xolair - omalizumab - EMEA/H/C/000606/X/0115/G .....	21
<b>4.3.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question .....</b>	<b>22</b>
4.3.1.	Eylea - aflibercept - EMEA/H/C/002392/X/0084/G .....	22
4.3.2.	Lumykras - sotorasib - EMEA/H/C/005522/X/0009 .....	22
4.3.3.	Talzenna - talazoparib - EMEA/H/C/004674/X/0015/G.....	22
4.3.4.	Upravi - selezipag - EMEA/H/C/003774/X/0038 .....	23
<b>4.4.</b>	<b>Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>23</b>
<b>4.5.</b>	<b>Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>23</b>

## 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 23

<b>5.1.</b>	<b>Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....</b>	<b>23</b>
5.1.1.	Abecma - idecabtagene vicleucef - Orphan - ATMP - EMEA/H/C/004662/II/0031 .....	23
5.1.2.	Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0107 .....	24
5.1.3.	Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0014.....	24
5.1.4.	Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011 .....	25
5.1.5.	Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0177/G25	
5.1.6.	Imjudo - tremelimumab - EMEA/H/C/006016/II/0001 .....	26
5.1.7.	Jardiance - empagliflozin - EMEA/H/C/002677/II/0074.....	26
5.1.8.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0134 .....	27
5.1.9.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0135 .....	27
5.1.10.	Lonsurf - trifluridine / tipiracil - EMEA/H/C/003897/II/0026 .....	28
5.1.11.	Mircera - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/II/0092 .....	28
5.1.12.	Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007 .....	29
5.1.13.	NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0058 .....	29
5.1.14.	Pepaxti - melphalan flufenamide - EMEA/H/C/005681/II/0002.....	30
5.1.15.	Praluent - alirocumab - EMEA/H/C/003882/II/0078 .....	30
5.1.16.	Prevymis - letermovir - Orphan - EMEA/H/C/004536/II/0033/G.....	31
5.1.17.	Reblozyl - luspatercept - Orphan - EMEA/H/C/004444/II/0021 .....	31
5.1.18.	Refixia - nonacog beta pegol - EMEA/H/C/004178/II/0032.....	32
5.1.19.	Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0013/G .....	32
5.1.20.	Soliris - Eculizumab - Orphan - EMEA/H/C/000791/II/0126.....	33
5.1.21.	Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0104/G34	
5.1.22.	Trodelyv - sacituzumab govitecan - EMEA/H/C/005182/II/0020.....	34
5.1.23.	Valdoxan - agomelatine - EMEA/H/C/000915/II/0051 .....	35
5.1.24.	Veyvondi - vonicog alfa - EMEA/H/C/004454/II/0030.....	35
5.1.25.	Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0037 .....	36
<b>5.2.</b>	<b>Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>36</b>
5.2.1.	Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020 .....	36
5.2.2.	SCENESSE - afamelanotide - Orphan - EMEA/H/C/002548/II/0044 .....	36
<b>5.3.</b>	<b>Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>37</b>

## 6. Medical devices 37

<b>6.1.</b>	<b>Ancillary medicinal substances - initial consultation .....</b>	<b>37</b>
-------------	--	-----------

6.1.1.	human albumin solution / gentamicin sulfate - EMEA/H/D/006141 .....	37
<b>6.2.</b>	<b>Ancillary medicinal substances – post-consultation update.....</b>	<b>37</b>
<b>6.3.</b>	<b>Companion diagnostics - initial consultation .....</b>	<b>37</b>
6.3.1.	in vitro diagnostic medical device - EMEA/H/D/006232.....	37
<b>6.4.</b>	<b>Companion diagnostics – follow-up consultation.....</b>	<b>38</b>
<b>7.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>38</b>
<b>7.1.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>38</b>
<b>8.</b>	<b>Pre-submission issues</b>	<b>38</b>
<b>8.1.</b>	<b>Pre-submission issue.....</b>	<b>38</b>
8.1.1.	avacincaptad pegol – H0006153 .....	38
8.1.2.	mRNA-1345 - H0006278.....	38
8.1.3.	Troriluzole hydrochloride - Orphan - H0006068 .....	38
<b>8.2.</b>	<b>Priority Medicines (PRIME).....</b>	<b>39</b>
8.2.1.	List of applications received.....	39
8.2.2.	Recommendation for PRIME eligibility .....	39
<b>9.</b>	<b>Post-authorisation issues</b>	<b>39</b>
<b>9.1.</b>	<b>Post-authorisation issues .....</b>	<b>39</b>
9.1.1.	Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/005639	
9.1.2.	Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan.....	39
9.1.3.	Brintellix - vortioxetine - EMEA/H/C/002717/II/0038 .....	40
<b>10.</b>	<b>Referral procedures</b>	<b>40</b>
<b>10.1.</b>	<b>Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 .....</b>	<b>40</b>
<b>10.2.</b>	<b>Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .</b>	<b>41</b>
10.2.1.	Colistimethate sodium (CMS) – EMEA/H/A-5(3)/1524 .....	41
<b>10.3.</b>	<b>Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 .....</b>	<b>41</b>
<b>10.4.</b>	<b>Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC .....</b>	<b>41</b>
<b>10.5.</b>	<b>Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....</b>	<b>41</b>
10.5.1.	Havrix and associated names - Inactivated hepatitis A virus - EMEA/H/A-30/1527.....	41
<b>10.6.</b>	<b>Community Interests - Referral under Article 31 of Directive 2001/83/EC .....</b>	<b>42</b>
<b>10.7.</b>	<b>Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....</b>	<b>42</b>
<b>10.8.</b>	<b>Procedure under Article 107(2) of Directive 2001/83/EC .....</b>	<b>42</b>
<b>10.9.</b>	<b>Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 .....</b>	<b>42</b>

<b>10.10.</b>	<b>Procedure under Article 29 of Regulation (EC) 1901/2006.....</b>	<b>42</b>
<b>10.11.</b>	<b>Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 .....</b>	<b>42</b>
<b>11.</b>	<b>Pharmacovigilance issue</b>	<b>42</b>
<b>11.1.</b>	<b>Early Notification System .....</b>	<b>42</b>
<b>12.</b>	<b>Inspections</b>	<b>43</b>
<b>12.1.</b>	<b>GMP inspections .....</b>	<b>43</b>
<b>12.2.</b>	<b>GCP inspections .....</b>	<b>43</b>
<b>12.3.</b>	<b>Pharmacovigilance inspections.....</b>	<b>43</b>
<b>12.4.</b>	<b>GLP inspections .....</b>	<b>43</b>
<b>13.</b>	<b>Innovation Task Force</b>	<b>43</b>
<b>13.1.</b>	<b>Minutes of Innovation Task Force.....</b>	<b>43</b>
<b>13.2.</b>	<b>Innovation Task Force briefing meetings.....</b>	<b>43</b>
<b>13.3.</b>	<b>Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 .....</b>	<b>43</b>
<b>13.4.</b>	<b>Nanomedicines activities .....</b>	<b>43</b>
<b>14.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>44</b>
<b>14.1.</b>	<b>Mandate and organisation of the CHMP .....</b>	<b>44</b>
14.1.1.	Vote by proxy .....	44
14.1.2.	CHMP membership.....	44
14.1.3.	Timetable for August 2023 Written Procedure .....	44
14.1.4.	CHMP learnings .....	44
14.1.5.	CHMP meetings .....	44
14.1.6.	Strategic review and learning meeting (SRLM) under Spanish EU presidency .....	44
<b>14.2.</b>	<b>Coordination with EMA Scientific Committees.....</b>	<b>45</b>
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC) .....	45
14.2.2.	Paediatric Committee (PDCO) .....	45
<b>14.3.</b>	<b>Coordination with EMA Working Parties/Working Groups/Drafting Groups .....</b>	<b>45</b>
14.3.1.	Biologics Working Party (BWP).....	45
14.3.2.	Nomination of Biologics Working Party (BWP) members.....	45
14.3.3.	Call for nominations for BWP Chair .....	45
14.3.4.	Nomination of Quality Working Party (QWP) members.....	46
14.3.5.	Call for nominations for QWP Chair and Vice-chair .....	46
14.3.6.	Nomination of Biosimilar Medicinal Products Working Party (BMWP) members .....	46
14.3.7.	Call for nominations for BMWP Chair.....	46
14.3.8.	Scientific Advice Working Party (SAWP) .....	47

14.3.9.	Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus Rev. 2 – Cardiovascular Working Party (CVSWP) .....	47
14.3.10.	CHMP Question to Healthcare Professionals Working Party (HCPWP).....	47
<b>14.4.</b>	<b>Cooperation within the EU regulatory network.....</b>	<b>47</b>
<b>14.5.</b>	<b>Cooperation with International Regulators.....</b>	<b>47</b>
<b>14.6.</b>	<b>Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee.....</b>	<b>47</b>
<b>14.7.</b>	<b>CHMP work plan .....</b>	<b>48</b>
<b>14.8.</b>	<b>Planning and reporting .....</b>	<b>48</b>
<b>14.9.</b>	<b>Others .....</b>	<b>48</b>
<b>15.</b>	<b>Any other business</b>	<b>48</b>
<b>15.1.</b>	<b>AOB topic.....</b>	<b>48</b>
15.1.1.	Update on COVID-19.....	48
15.1.2.	Control options for nitrosamines .....	48
15.1.3.	Gap analysis assessment in support of member state shortage management activities.....	48
15.1.4.	Product Information for upcoming Comirnaty and Spikevax variant vaccine.....	48
15.1.5.	Preparation of oncology product-related discussions .....	49
15.1.6.	Update on EMA collaborative systems .....	49
<b>List of participants</b>		<b>50</b>
<b>Explanatory notes</b>		<b>55</b>

# 1. Introduction

## 1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

## 1.2. Adoption of agenda

CHMP agenda for 19-22 June 2023.

The CHMP adopted the agenda.

## 1.3. Adoption of the minutes

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 12 June 2023.

The CHMP adopted the minutes from the PROM meeting held on 12 June 2023.

CHMP minutes for 22-25 May 2023.

The minutes of the CHMP 22–25 May meeting were adopted via written procedure on 30 June 2023.



## 2. Oral Explanations

### 2.1. Pre-authorisation procedure oral explanations

#### 2.1.1. adagrasib - EMEA/H/C/006013

---

Treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: Oral explanation

**Action:** Oral explanation to be held on 20 June 2023 at 16:00

List of Outstanding Issues adopted on 25.05.2023, 23.02.2023. List of Questions adopted on 15.09.2022.

An oral explanation was held on 20 June 2023. The presentation by the MAH focused on the clinical data in support of the application.

#### 2.1.2. gefapixant - EMEA/H/C/005884

---

Treatment of refractory or unexplained chronic cough

Scope: Possible oral explanation

**Action:** Oral explanation to be held on 21 June 2023 at 14:00

List of Outstanding Issues adopted on 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

#### 2.1.3. gefapixant - EMEA/H/C/005476

---

Treatment of refractory or unexplained chronic cough

Scope: Possible oral explanation

**Action:** Oral explanation to be held on 21 June 2023 at 14:00

List of Outstanding Issues adopted on 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

#### 2.1.4. natalizumab - EMEA/H/C/005752

---

Therapy for active relapsing remitting multiple sclerosis (RRMS)

Scope: Oral explanation

**Action:** Oral explanation to be held on 19 June 2023 at 14:00

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 10.11.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

## 2.2. Re-examination procedure oral explanations

### 2.2.1. Lagevrio - molnupiravir - EMEA/H/C/005789

---

Merck Sharp & Dohme B.V.; treatment of coronavirus disease 2019 (COVID-19)

Scope: Oral explanation

**Action:** Oral explanation to be held on 20 June 2023 at 14:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.02.2023. List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 24.02.2022, 16.12.2021.

The CHMP noted that the applicant waved the request for an oral explanation.

See 3.5

## 2.3. Post-authorisation procedure oral explanations

No items

## 2.4. Referral procedure oral explanations

No items

# 3. Initial applications

## 3.1. Initial applications; Opinions

### 3.1.1. Albrioz - sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901

---

Amylyx Pharmaceuticals EMEA B.V.; treatment of amyotrophic lateral sclerosis (ALS)

Scope: Opinion; third party interventions

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.02.2023, 10.11.2022. List of Questions adopted on 23.06.2022.

The Committee was reminded of the status of this application, and they noted the third party interventions.

The Committee adopted a negative opinion by consensus recommending the refusal of the granting of the marketing authorisation. The CHMP assessment report was adopted.

The question-and-answer document was circulated for information.

### 3.1.2. [Aquipta - atogepant - EMEA/H/C/005871](#)

---

AbbVie Deutschland GmbH & Co. KG; Prophylaxis of migraine in adults who have at least 4 migraine days per month.

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.03.2023. List of Questions adopted on 10.11.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that atogepant is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.3. [Jesduvroq - daprodustat - EMEA/H/C/005746](#)

---

Glaxosmithkline Trading Services Limited; treatment of anaemia associated with chronic kidney disease (CKD) in adults

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023, 30.03.2023, 10.11.2022. List of Questions adopted on 23.06.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that daprodustat is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

## 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

### 3.2.1. respiratory syncytial virus vaccines - EMEA/H/C/006027

---

#### **Accelerated assessment**

Prevention of respiratory tract disease

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 24.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.2. dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009

---

Norgine B.V.; treatment of malignant hyperthermia (including suspected cases)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 10.11.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

### 3.2.3. enalapril maleate - PUMA - EMEA/H/C/005731

---

Treatment of heart failure

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 25.05.2023, 23.02.2023. List of Questions adopted on 21.07.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3<sup>rd</sup> list of outstanding issues with a specific timetable.

### 3.2.4. latanoprost - EMEA/H/C/005933

---

Reduction of elevated intraocular pressure (IOP)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 26.01.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.5. [gefapixant - EMEA/H/C/005884](#)

---

Treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021.

List of Questions adopted on 24.06.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 5<sup>th</sup> list of outstanding issues with a specific timetable.

### 3.2.6. [gefapixant - EMEA/H/C/005476](#)

---

Treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021.

List of Questions adopted on 24.06.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 5<sup>th</sup> list of outstanding issues with a specific timetable.

### 3.2.7. [talquetamab - PRIME - Orphan - EMEA/H/C/005864](#)

---

#### **Accelerated assessment**

Janssen-Cilag International N.V.; monotherapy treatment of adult patients with relapsed and refractory multiple myeloma

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 24.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding

---

issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.8. [natalizumab - EMEA/H/C/005752](#)

---

Therapy for active relapsing remitting multiple sclerosis (RRMS)

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 10.11.2022.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.9. [fezolinetant - EMEA/H/C/005851](#)

---

Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 26.01.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed with the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues with a specific timetable.

### 3.2.10. [zilucoplan - Orphan - EMEA/H/C/005450](#)

---

UCB Pharma S.A.; treatment of generalised myasthenia gravis in adults

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 26.01.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

#### 3.3.1. methylphenidate hydrochloride - PUMA - EMEA/H/C/005975

---

Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.2. buprenorphine - EMEA/H/C/006188

---

Treatment of opioid drug dependence

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.3. rdESAT-6 / rCFP-10 - EMEA/H/C/006177

---

Diagnosis of infection with Mycobacterium tuberculosis

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.4. sugemalimab - EMEA/H/C/006088

---

Treatment of adults with metastatic non-small cell lung cancer (NSCLC)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.5. [aprocitentan - EMEA/H/C/006080](#)

---

Treatment of resistant hypertension

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

## 3.4. **Update on on-going initial applications for Centralised procedure**

### 3.4.1. [polihexanide - Orphan - EMEA/H/C/005858](#)

---

SIFI SPA; For the treatment of acanthamoeba keratitis

Scope: Letter by the applicant dated 16.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in September 2022.

**Action:** For adoption

List of Questions adopted on 15.09.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2022.

### 3.4.2. [aumolertinib - EMEA/H/C/006069](#)

---

Treatment of non-small cell lung cancer

Scope: Letter by the applicant dated 09.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in March 2023.

**Action:** For adoption

List of Questions adopted on 30.03.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2023.

### 3.4.3. [exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763](#)

---

Vertex Pharmaceuticals (Ireland) Limited; treatment of transfusion-dependent  $\beta$ -thalassemia and sickle cell disease

Scope: Letter by the applicant requesting a change to the clock stop to respond to the list of questions adopted in May 2023.

**Action:** For information

List of Questions adopted on 17.05.2023.

The CHMP noted the timetable as adopted by CAT.



#### 3.4.4. [dabigatran etexilate - EMEA/H/C/006023](#)

---

Prevention of venous thromboembolic events

Scope: Letter by the applicant dated 14.06.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in March 2023.

**Action:** For adoption

List of outstanding issues adopted on 30.03.2023. List of Questions adopted on 21.07.2022.

The CHMP did not agree to the request by the applicant for an extension but agreed to a shorter extension to the clock stop to respond to the list of outstanding issues adopted in March 2023.

#### 3.4.5. [omecamtiv mecarbil - EMEA/H/C/006112](#)

---

Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%

Scope: Letter by the applicant dated 09.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in April 2023.

**Action:** For adoption

List of questions adopted on 26.04.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2023.

#### 3.4.6. [bevacizumab - EMEA/H/C/005723](#)

---

Treatment of neovascular (wet) age-related macular degeneration (nAMD).

Scope: Letter by the applicant dated 09.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in April 2023.

**Action:** For adoption

List of questions adopted on 26.04.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2023.

#### 3.4.7. [omaveloxolone - Orphan - EMEA/H/C/006084](#)

---

Reata Ireland Limited; Treatment of Friedreich's ataxia

Scope: Letter by the applicant dated 06.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in April 2023.

**Action:** For adoption

List of questions adopted on 26.04.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2023.

### 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

#### 3.5.1. Lagevrio - molnupiravir - EMEA/H/C/005789

---

Merck Sharp & Dohme B.V.; treatment of coronavirus disease 2019 (COVID-19)

Scope: Opinion

**Action:** For adoption

Opinion adopted on 23.02.2023. List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 24.02.2022, 16.12.2021.

See 2.2

The CHMP noted that the applicant waved the request for an oral explanation.

The Committee noted the withdrawal of the re-examination request.

### 3.6. Initial applications in the decision-making phase

No items

### 3.7. Withdrawals of initial marketing authorisation application

#### 3.7.1. Dyrupeg - pegfilgrastim - EMEA/H/C/005810

---

CuraTeQ Biologics s.r.o; Treatment of neutropenia

Scope: Withdrawal of marketing authorisation application

**Action:** For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of outstanding issues adopted on 13.10.2022. List of Questions adopted on 27.01.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

#### 3.7.2. Zefylti - filgrastim - EMEA/H/C/005888

---

CuraTeQ Biologics s.r.o; Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection

Scope: Withdrawal of marketing authorisation application

**Action:** For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of outstanding issues adopted on 10.11.2022. List of Questions adopted on 23.06.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

## 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Adtralza - tralokinumab - EMEA/H/C/005255/X/0007

---

LEO Pharma A/S

Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension application to add a new strength of 300 mg (150 mg/ml) tralokinumab solution for injection in pre-filled pen for subcutaneous administration. The RMP (version 1.1) is updated accordingly."

**Action:** For adoption

List of Questions adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 4.1.2. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0176

---

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new strength of 1.5/1.5 µg (tozinameran, famtozinameran) for active immunisation in infants and children between 6 months to 4 years of age."

**Action:** For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 4.1.3. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0180

---

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new pharmaceutical form of Comirnaty 5/5 µg (tozinameran, famtozinameran) dispersion for injection for active immunisation for children

aged 5 to 11 years of age.”

**Action:** For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 4.1.4. Erleada - apalutamide - EMEA/H/C/004452/X/0028/G

---

Janssen-Cilag International N.V.

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Tiphaine Vaillant

Scope: “Extension application to add a new strength (240 mg) film-coated tablets grouped with the IB variation (C.I.z).

The RMP (version 6.1) has also been submitted.

C.I.z (IB): to align the SmPC/PL for Erleada 60 mg with the SmPC/PL proposed for the registration of the new Erleada film-coated tablet strength, 240 mg.

The PL for Erleada 60 mg is proposed to be updated to ensure consistency.

In addition, few minor revisions are proposed to the SmPC for Erleada 60 mg, to align the SmPC proposed for the 240 mg strength:

- SmPC sections 5.1 and 5.2: Orthographic corrections
- SmPC section 6.5: Further details on the description of the current packaging have been added, this change does not result from a change to the container.
- SmPC section 6.6: The title of the section has been aligned with QRD template.”

**Action:** For adoption

List of Questions adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### 4.1.5. Ofev - nintedanib - EMEA/H/C/003821/X/0052/G

---

Boehringer Ingelheim International GmbH

Rapporteur: Finbarr Leacy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: “Extension application to add a new strength of 25 mg soft capsule grouped with a type II variation C.I.6.a to add a new indication of treatment of fibrosing Interstitial Lung Diseases (ILDs) in children and adolescents from 6 to 17 years of age, based on results from study 1199 0337 (InPedILD); a randomised, placebo-controlled, double-blind, multicentre, multinational, phase III clinical trial undertaken to evaluate dose-exposure and safety of nintedanib on top of standard of care in children and adolescents (6 to 17 years old) with clinically significant fibrosing ILD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes

to the list of local representatives in the Package Leaflet. The updated RMP version 12.0 is also submitted.”

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

#### **4.1.6. Tenkasi - oritavancin - EMEA/H/C/003785/X/0036**

---

Menarini International Operations Luxembourg S.A.

Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski

Scope: “Extension application to add a new strength of 1200 mg for powder for concentrate for solution for infusion. The RMP (version 4) is updated in accordance.”

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023, 23.02.2023. List of Questions adopted on 21.07.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

## **4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

### **4.2.1. Xolair - omalizumab - EMEA/H/C/000606/X/0115/G**

---

Novartis Europharm Limited

Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn

Scope: “Extension application to add a new strength of 300 mg (150 mg/ml) for Xolair solution for injection grouped with quality type II, IB and IAIN variations. The RMP (version 17.0) is updated in accordance.

**Action:** For adoption

List of Questions adopted on 15.12.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to quality aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

### 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

#### 4.3.1. Eylea - aflibercept - EMEA/H/C/002392/X/0084/G

---

Bayer AG

Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault

Scope: "Extension application to add a new strength of Aflibercept 114.3 mg/ml solution for injection (in a vial), to be indicated in adults for the (1) treatment of neovascular (wet) age-related macular degeneration (nAMD) and (2) visual impairment due to diabetic macular oedema (DME), grouped with a type II variation (B.II.g.2) to introduce a post-approval change management protocol to add a new presentation for Aflibercept solution 114.3 mg/ml in a single-use pre-filled syringe for intravitreal injection."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy and safety aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.2. Lumykras - sotorasib - EMEA/H/C/005522/X/0009

---

Amgen Europe B.V.

Rapporteur: Alexandre Moreau

Scope: "Extension application to add a new strength of 240 mg film-coated tablet."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to quality and PK aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.3. Talzenna - talazoparib - EMEA/H/C/004674/X/0015/G

---

Pfizer Europe MA EEIG

Rapporteur: Filip Josephson, Co-Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: "Extension application for Talzenna to introduce a new strength of 0.1 mg hard capsules, grouped with a type II variation (C.I.6.a) in order to extend the indication for Talzenna in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), based on final results from study C3441021 (TALAPRO-2) as well as supplemental data from study C3441006 (TALAPRO-1). Study C3441021 (TALAPRO-2) is a randomized, double-blind, placebo-controlled, phase 3 study of talazoparib in combination with enzalutamide in mCRPC, while study C3441006 (TALAPRO-1) is a phase 2, open-label, response rate study of talazoparib in men with DNA

repair defects and mCRPC who previously received taxane-based chemotherapy and progressed on at least one novel hormonal agent. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.5, 4.7, 4.8, 5.1, 5.2, 6.1, 6.5 and 8 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical safety.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.3.4. [Uptravi - selexipag - EMEA/H/C/003774/X/0038](#)

---

Janssen-Cilag International N.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault

Scope: “Extension application to add a new strength of 100 µg film-coated tablets in HDPE bottle. The RMP (version 10.1) is updated in accordance.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.4. **Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

#### 4.5. **Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

### 5. **Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008**

#### 5.1. **Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information**

##### 5.1.1. [Abecma - idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662/II/0031](#)

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjekken, Co-Rapporteur: Heli Suila, CHMP Coordinators: Ingrid Wang,

Johanna Lähteenvuo, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMA-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The CHMP was updated on discussions at the CAT. The Committee discussed the issues identified in this application relating to the RMP.

The Committee endorsed the request for supplementary information with a specific timetable as adopted by CAT.

#### 5.1.2. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0107

Takeda Pharma A/S

Rapporteur: Johann Lodewijk Hillege

Scope: "Extension of indication to include treatment of adult patients with previously untreated CD30+ advanced (including Stage III) Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine and dacarbazine (AVD), for Adcetris, based on the second interim analysis of OS data from ECHELON-1 study (C25003); this is a randomized, open-label, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical HL. As a consequence, sections 4.1 and 5 of the SmPC are updated."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.3. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0014

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with obinutuzumab treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic treatments for Brukinsa; based on results from studies BGB-3111-212 and BGB-3111-GA101-001. BGB-3111-212 is an ongoing international, Phase 2, open-label, randomized (2:1), active control study of zanubrutinib plus obinutuzumab (Arm A) versus



obinutuzumab monotherapy (Arm B) in patients with R/R FL. The primary efficacy endpoint is overall response rate (ORR); while BGB-3111-GA101-001 is a Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-Cell Lymphoid Malignancies. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to nonclinical, clinical, pharmacovigilance and RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.4. [Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011](#)

---

Albireo

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: “Extension of indication to include treatment of cholestasis and pruritus in Alagille syndrome (ALGS) in patients from birth and older for Bylvay, based on final results from study A4250-012 and interim results from study A4250-015. Study A4250-012 is a 24-week, randomised, double-blind, placebo-controlled Phase III study conducted in 52 patients with a genetically confirmed diagnosis of ALGS and presence of pruritus and high serum bile acid levels at baseline. Study A4250-015 is an ongoing 72-week open-label extension trial for patients who completed study A4250-012 and evaluates the long-term safety and efficacy of Bylvay in patients with ALGS. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application relating to nonclinical and RMP aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.5. [Comirnaty - COVID-19 mRNA vaccine \(nucleoside-modified\) - EMEA/H/C/005735/II/0177/G](#)

---

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: “C.I.6: Extension of indication to include Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection and Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection for use as primary vaccination course against COVID-19 in children aged 5 to 11 years and in individuals 12 years of age and older, respectively, based on interim results from studies C4591044 and C4591048.

Study C4591044 is an interventional, randomized, active-controlled, phase 2/3 study to investigate the safety, tolerability, and immunogenicity of bivalent BNT162b RNA-based vaccine candidates as a booster dose in COVID-19 vaccine-experienced healthy individuals, while study C4591048 is a phase 1/2/3 master study to investigate the safety, tolerability, and immunogenicity of a bivalent BNT162b2 RNA-based vaccine candidate. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

A.6: To change the ATC Code of tozinameran, riltozinameran and famtozinameran from J07BX03 to J07BN01.”

**Action:** For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.6. Imjudo - tremelimumab - EMEA/H/C/006016/II/0001

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia

Scope: “Extension of indication to include in combination with durvalumab and platinum-based chemotherapy, the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations for Imjudo, based on the final analysis from the pivotal study D419MC00004, a Randomised, Multi-center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON). As a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to include editorial changes.”

**Action:** For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.7. Jardiance - empagliflozin - EMEA/H/C/002677/II/0074

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Karin Janssen van Doorn, PRAC

Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to include treatment of chronic kidney disease (CKD) in adults, based on final results from study EMPA-KIDNEY (1245-0137) listed as a category 3 study in the RMP; this is a Phase III, multicentre international randomised parallel group double-blind placebo controlled clinical trial of empagliflozin once daily to assess cardio-renal outcomes in patients with chronic kidney disease. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 20.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.3."

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.8. [Keytruda - pembrolizumab - EMEA/H/C/003820/II/0134](#)

---

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant, treatment of resectable stage II, IIIA, or IIIB (T3 4N2) non-small cell lung carcinoma in adults for Keytruda based on study KEYNOTE-671, a phase III, randomized, double-blind trial of platinum doublet chemotherapy +/- pembrolizumab as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 41.1 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.9. [Keytruda - pembrolizumab - EMEA/H/C/003820/II/0135](#)

---

Merck Sharp & Dohme B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with chemotherapy the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults based on study KEYNOTE-859, a randomized, double-blind phase 3 trial, evaluating Keytruda in combination with chemotherapy compared to placebo in combination with chemotherapy for the first-line treatment of patients with HER2-negative locally advanced unresectable or metastatic

gastric or GEJ adenocarcinoma. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 42.1 of the RMP has also been submitted.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.10. Lonsurf - trifluridine / tipiracil - EMEA/H/C/003897/II/0026

Les Laboratoires Servier

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Extension of indication to include treatment of patients with refractory metastatic colorectal cancer, for Lonsurf in combination with bevacizumab based on results from study SUNLIGHT (CL3-95005-007); This is an open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. The updated RMP version 10 has also been submitted. In addition, the MAH took the opportunity to update section 4.6 of the SmPC and the package leaflet accordingly.”

**Action:** For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.11. Mircera - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/II/0092

Roche Registration GmbH

Rapporteur: Maria Concepcion Prieto Yerro

Scope: “Extension of indication to include treatment of paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instruction for Use in the Package Leaflet.”

**Action:** For adoption

Request for Supplementary Information adopted on 23.02.2023, 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.12. Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007

---

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include chronic weight management, including weight loss and weight maintenance, for Mounjaro, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of  $\geq 30$  kg/m<sup>2</sup> (obesity), or  $\geq 27$  kg/m<sup>2</sup> to  $< 30$  kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbid condition, based on a global, pivotal phase 3 study I8F-MC-GPHK (SURMOUNT-1) and five supportive phase 3 studies (SURPASS-1 to -5) in participants with T2DM and BMI  $\geq 27$  kg/m<sup>2</sup>. SURMOUNT-1 is a phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight related comorbidities. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The Committee discussed the issues identified in this application relating to nonclinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.13. NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0058

---

MediWound Germany GmbH

Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber

Scope: "Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2 arm study aiming to demonstrate the superiority of NexoBrid treatment over SOC treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA).

As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 9 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 15.12.2022.

The Committee discussed the issues identified in this application relating to clinical aspects.  
The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.14. [Pepaxti - melphalan flufenamide - EMEA/H/C/005681/II/0002](#)

---

Oncopeptides AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of patients with Multiple Myeloma who have received at least two prior lines of therapies for Pepaxti, based on final results from study OP-103 OCEAN; this is a randomized, open-label phase III study in patients with relapsed or refractory multiple myeloma following two to four lines of prior therapies and who were refractory to lenalidomide and the last line of therapy. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application relating to clinical and RMP aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.15. [Praluent - alirocumab - EMEA/H/C/003882/II/0078](#)

---

Sanofi Winthrop Industrie

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment of paediatric patients 8 years of age and older with heterozygous familial hypercholesterolemia (HeFH) as an adjunct to diet, alone or in combination with other LDL-C lowering therapies, based on final results from study EFC14643 listed as a category 3 study in the RMP; this is a randomized, double-blind, placebo-controlled study followed by an open-label treatment period to evaluate the efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolemia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP is also submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy/safety aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.16. Prevmis - letermovir - Orphan - EMEA/H/C/004536/II/0033/G

---

Merck Sharp & Dohme B.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Kirsti Villikka

Scope: "Grouped application consisting of 1) Extension of indication to include prophylaxis of cytomegalovirus in kidney transplant recipients (KTR) for Prevmis, based on final results from study P002MK8228; this is a Phase III, randomized, double-blind, active comparator-controlled study to evaluate the efficacy and safety of letermovir versus valganciclovir for the prevention of Human Cytomegalovirus (CMV) Disease in adult kidney transplant recipients. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes; 2) Update of section 4.2 of the SmPC in order to update duration of treatment recommendation based on final results from study P040MK8228; this is a Phase III randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+) of an allogeneic hematopoietic stem cell transplant (HSCT)."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical and RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.17. Reblozyl - luspatercept - Orphan - EMEA/H/C/004444/II/0021

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Daniela Philadelphia, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Jo Robays

Scope: "Extension of indication to include treatment of adult patients with anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS), who may require RBC transfusions for Reblozyl, based on results from study ACE-536-MDS-002 (COMMANDS), an active-controlled, open-label, randomized Phase 3 study comparing the efficacy and safety of luspatercept vs epoetin alfa in adult subjects with anemia due to IPSS-R very low, low or intermediate risk MDS, who are ESA naïve and require RBC transfusions, and studies ACE-536-MDS-001 (MEDALIST), ACE-536-MDS-004, A536-03, A536-05 and ACE-536-LTFU-001; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy aspects.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.18. Refixia - nonacog beta pegol - EMEA/H/C/004178/II/0032

---

Novo Nordisk A/S

Rapporteur: Daniela Philadelphia, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment and prophylaxis of bleeding in children below 12 years of age with haemophilia B including previously untreated patients for Refixia, based on interim results from studies NN7999-3774 and NN7999-3895. NN7999-3774 is a multicentre, open-label, non-controlled study evaluating the safety, efficacy and pharmacokinetics of nonacog beta pegol in previously treated children with haemophilia B, while NN7999-3895 is a multicentre, open-label, single-arm, non-controlled trial evaluating the safety and efficacy of nonacog beta pegol in previously untreated patients with haemophilia B. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 5.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The Committee adopted the similarity assessment report.

### 5.1.19. Ryego - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0013/G

---

Gedeon Richter Plc.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of moderate to severe pain associated with endometriosis for Ryego in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis, based on final results from studies MVT-601-3101 and MVT-601-3102 and final results up to 104 weeks from study MVT-601-3103. Studies 3101 and 3102 are pivotal, phase III, randomised, double-blind, placebo-controlled, safety and efficacy studies to evaluate relugolix with E2 and NETA as a combination therapy for pain associated with endometriosis. Study 3103 is an open-label extension study including patients who completed one of the two pivotal studies and met the eligibility criteria, regardless of their treatment assignment in the pivotal studies. In the extension part all patients received relugolix combination therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC were updated. The Package Leaflet is updated in accordance.

Update of section 4.5 of the SmPC to update information regarding Drug-Drug Interaction based on final results of DDI studies MVT-601-54, MVT-601-55 and MVT-601-57. Study



MVT-601-54 is a 2-part interventional open-label study to assess the potential effects of erythromycin on the PK of the 3 components of Ryeqo. Study MVT-601-55 is an interventional open label fixed single sequence cross-over study to assess whether a 6-hour dose separation is sufficient to mitigate absorption mediated increased exposure to relugolix and study MVT-601-057 is a 2-part study to assess the potential effect of relugolix on the PK of total dabigatran.

The updated RMP version (2.0) has also been submitted. As part of the application, the MAH also requests an extension of the market protection by one additional year." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 23.02.2023.

The Committee discussed the issues identified in this application relating to clinical and SmPC aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.20. Soliris - Eculizumab - Orphan - EMEA/H/C/000791/II/0126

---

Alexion Europe SAS

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension of indication to include treatment of paediatric patients with refractory generalised myasthenia gravis (gMG) for Soliris, based on interim results from study ECU-MG-303; this is an open-label, multicenter, phase 3 study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of intravenous (IV) eculizumab in paediatric patients aged 6 to less than 18 years with acetylcholine receptor-antibody (AChR-Ab) positive (+) refractory gMG. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 20.3 of the RMP has been agreed. In addition, the MAH took the opportunity to update section 4.8 of the SmPC in order to update the frequency of the list of adverse drug reactions (ADRs) based on cumulative safety data and to introduce minor editorial changes to the PI. In addition, in line with the new WHO level alteration, the marketing authorisation holder (MAH) took the opportunity to update the ATC code in the SmPC section 5.1. The list of local representatives in the Package Leaflet has been updated."

**Action:** For adoption

Request for Supplementary Information adopted on 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.21. Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0104/G

---

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Grouped variation:

- C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection as a two-dose primary vaccination course in children 6 months through 5 years of age, based on data from study mRNA-1273-P306 (NCT05436834), an Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years; as a consequence, sections 2, 4.1, 4.2 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 6.7 of the RMP has also been submitted.

- C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 as a single-dose primary vaccination course against COVID-19 in individuals 6 years of age and older, irrespective of vaccination history, based on epidemiology and clinical data from study P306 part 1; as a consequence, sections 2, 4.1, 4.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, the marketing authorisation holder (MAH) took the opportunity to make minor editorial changes/corrections throughout the product information."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.22. Trodelvy - sacituzumab govitecan - EMEA/H/C/005182/II/0020

---

Gilead Sciences Ireland UC

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting based on final results from study IMMU-132-09 (TROPiCS-02); this is an open-label, randomized, multicenter phase 3 study of sacituzumab govitecan (IMMU-132) versus treatment of physician's choice (TPC) in subjects with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer (mBC) who have failed at least two prior chemotherapy regimens. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet (PL) is updated accordingly. Version 3.0 of the RMP is approved. The MAH has also taken the opportunity to introduce minor modifications to the product information related to the QRD Template and SmPC guideline.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

#### 5.1.23. Valdoxan - agomelatine - EMEA/H/C/000915/II/0051

---

Les Laboratoires Servier

Rapporteur: Eva Skovlund, PRAC Rapporteur: Pernille Harg

Scope: "Extension of indication to include a new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone, for Valdoxan, further to the results of the phase 2 (CL2-20098-075) and phase 3 (CL3-20098-076) paediatric clinical studies included in the Paediatric Investigation Plan number EMEA-001181-PIP-11; As a consequence, the sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. The updated RMP version 25.1 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 26.01.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.24. Veyvondi - vonicog alfa - EMEA/H/C/004454/II/0030

---

Baxalta Innovations GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include "prophylactic treatment to prevent or reduce the frequency of bleeding episodes" for Veyvondi based on final results from study 071301 and interim results from study SHP677-304. Study 071301 is a prospective, phase 3, open-label, international multicenter study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand disease; while study SHP677-304 is a phase 3B, prospective, open-label, uncontrolled, multicenter study on long-term safety and efficacy of rVWF in paediatric and adult subjects with severe von Willebrand disease. As a consequence, sections 4.1, 4.2, 4.4, 5.1, 5.2, 6.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical, SmPC and RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.25. Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0037

---

Merck Sharp & Dohme B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include treatment of the paediatric population (1 to 18 years of age) for Zinplava, based on final results from study MK-6072-001 (MODIFY III) listed as a category 3 study in the RMP; this is a phase 3, randomised, placebo-controlled, parallel-group, multi-site, double-blind trial evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of a single infusion of bezlotoxumab in paediatric participants from 1 to <18 years of age receiving antibacterial drug treatment for Clostridioides difficile infection (CDI). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

## 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

### 5.2.1. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020

---

GW Pharma (International) B.V.

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Tomas Radimersky, PRAC

Rapporteur: Ana Sofia Diniz Martins

Scope: Final assessment report re-tabled

**Action:** For information

Opinion adopted on 26.04.2023. Request for Supplementary Information adopted on 30.03.2023, 15.12.2022, 15.09.2022.

The CHMP noted the re-tabled final assessment report.

### 5.2.2. SCENESSE - afamelanotide - Orphan - EMEA/H/C/002548/II/0044

---

Clinuvel Europe Limited

Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication for the prevention of phototoxicity in adolescent patients (12 to under 18 years of age) with erythropoietic protoporphyria (EPP), based on the analysis of the safety and efficacy data available. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.4 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce a

minor editorial correction to the PI.”

Request by the applicant for an extension to the clock stop to respond to the RSI adopted in May 2023.

**Action:** For adoption

Request for Supplementary Information adopted on 25.05.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the RSI adopted in May 2023.

### **5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

## **6. Medical devices**

### **6.1. Ancillary medicinal substances - initial consultation**

#### **6.1.1. human albumin solution / gentamicin sulfate - EMEA/H/D/006141**

---

Human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: Opinion

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 10.11.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

### **6.2. Ancillary medicinal substances – post-consultation update**

No items

### **6.3. Companion diagnostics - initial consultation**

#### **6.3.1. in vitro diagnostic medical device - EMEA/H/D/006232**

---

To detect rearrangements involving the ALK gene via fluorescence

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP the list of questions with a specific timetable.

#### 6.4. Companion diagnostics – follow-up consultation

No items

### 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

#### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

### 8. Pre-submission issues

#### 8.1. Pre-submission issue

##### 8.1.1. avacincaptad pegol – H0006153

Treatment of adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

##### 8.1.2. mRNA-1345 - H0006278

Active immunisation for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) in individuals 60 years of age and older

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

##### 8.1.3. Troriluzole hydrochloride - Orphan - H0006068

Biohaven Bioscience Ireland Limited; Treatment of hereditary spinocerebellar ataxia

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

## 8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

### 8.2.1. List of applications received

---

**Action:** For information

The CHMP noted the information.

### 8.2.2. Recommendation for PRIME eligibility

---

**Action:** For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 1 recommendation for eligibility to PRIME: 1 was denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

## 9. Post-authorisation issues

### 9.1. Post-authorisation issues

#### 9.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

---

Orexigen Therapeutics Ireland Limited

Scope: Re-examination; List of questions to the SAG

**Action:** For adoption

Opinion adopted on 30.03.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022, 24.03.2022.

The CHMP adopted the list of questions to the SAG.

#### 9.1.2. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

---

GlaxoSmithKline (Ireland) Limited

Rapporteur: Johanna Lähteenvuori, Co-Rapporteur: Carolina Prieto Fernandez, PRAC

Rapporteur: Ulla Wändel Liminga

Scope: Renewal of conditional marketing authorisation

**Action:** For adoption

Request for Supplementary Information adopted on 26.04.2023.

The Committee discussed the issues identified in this application.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of questions to this expert group.

### 9.1.3. [Brintellix - vortioxetine - EMEA/H/C/002717/II/0038](#)

---

H. Lundbeck A/S

Rapporteur: Karin Janssen van Doorn

Scope: "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to include clinically relevant information on the efficacy, safety, tolerability and PK of vortioxetine in the paediatric population based on final results from studies 12709A, 12712A and 12712B. Study 12709A is an interventional, randomized, double-blind, placebo-controlled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) to evaluate efficacy and safety. Whereas studies 12712A and 12712B are 2 open-label, long-term safety and efficacy studies in children and adolescents: one 6-month extension study (study 12712A) to studies 12709A and 12710A, and one 18-month extension study (study 12712B) to study 12712A. The Package Leaflet is updated accordingly. In addition, updates are proposed in section 4.5 and package leaflet section 2 in relation to NSAIDs as well as updates to the package leaflet section 4 to align SmPC wording on sexual dysfunction."

**Action:** For adoption

Request for Supplementary Information adopted on 30.03.2023, 15.12.2022.

The Committee discussed the issues identified in this application relating to SmPC aspects.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

## 10. Referral procedures

### 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items



## **10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004**

### **10.2.1. Colistimethate sodium (CMS) – EMEA/H/A-5(3)/1524**

---

Various MAHs

Referral Rapporteur: Martina Weise, Referral Co-Rapporteur: Ewa Balkowiec Iskra

Review of the ratio of polymyxins E1 and E2 in colistin starting material and of the (sulfomethylation) composition profile of CMS finished product.

Scope: List of questions

**Action:** For adoption

The CHMP adopted a list of questions with a specific timetable.

CHMP list of questions: June 2023 CHMP

Submission of responses: 26.10.2023

Re-start of the procedure: 16.11.2023

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 02.02.2024

Comments: 09.02.2024

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 15.02.2024

CHMP list of outstanding issues/CHMP opinion: February 2024 CHMP

## **10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**

No items

## **10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

No items

## **10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

### **10.5.1. Havrix and associated names - Inactivated hepatitis A virus - EMEA/H/A-30/1527**

---

MAH: GlaxoSmithKline Biologicals

Referral Rapporteur: Armando Genazzani, Referral Co-Rapporteur: Ilko Getov

Harmonisation exercise for Havrix and associated names. Product Information harmonisation was triggered by the MAH.

Scope: Appointment of referral rapporteurs

**Action:** For adoption

The CHMP appointed Armando Genazzani as Referral Rapporteur and Ilko Getov as Referral Co-Rapporteur.

#### **10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC**

No items

#### **10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC**

No items

#### **10.8. Procedure under Article 107(2) of Directive 2001/83/EC**

No items

#### **10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003**

No items

#### **10.10. Procedure under Article 29 of Regulation (EC) 1901/2006**

No items

#### **10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008**

No items

## **11. Pharmacovigilance issue**

### **11.1. Early Notification System**

June 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action:** For information

The CHMP noted the information.

## **12. Inspections**

### **12.1. GMP inspections**

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

### **12.2. GCP inspections**

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

### **12.3. Pharmacovigilance inspections**

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

### **12.4. GLP inspections**

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

## **13. Innovation Task Force**

### **13.1. Minutes of Innovation Task Force**

No items

### **13.2. Innovation Task Force briefing meetings**

No items

### **13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004**

No items

### **13.4. Nanomedicines activities**

No items

## 14. Organisational, regulatory and methodological matters

### 14.1. Mandate and organisation of the CHMP

#### 14.1.1. Vote by proxy

---

Ilko Getov gave a proxy to Bruno Sepodes for the whole meeting.

#### 14.1.2. CHMP membership

---

No topics

#### 14.1.3. Timetable for August 2023 Written Procedure

---

**Action:** For adoption

The CHMP endorsed the timetable for the August 2023 written procedure.

#### 14.1.4. CHMP learnings

---

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

**Action:** For discussion

The CHMP noted the learnings identified during the June plenary meeting. The CHMP adopted the learnings from the May meeting.

#### 14.1.5. CHMP meetings

---

Alternating face-to-face and virtual meetings.

**Action:** For discussion

The CHMP discussed the meeting frequency of face/to-face versus remote plenary meetings.

#### 14.1.6. Strategic review and learning meeting (SRLM) under Spanish EU presidency

---

Information on the SRLM, to be held 17-18 October 2023 in Madrid

CHMP: Maria Concepcion Prieto Yerro

**Action:** For information

The CHMP noted the information.

## 14.2. Coordination with EMA Scientific Committees

### 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

---

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for June 2023

**Action:** For adoption

The CHMP adopted the EURD list.

### 14.2.2. Paediatric Committee (PDCO)

---

Agenda of the June 2023 PDCO plenary meeting

**Action:** For information

The CHMP noted the PDCO agenda.

## 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 14.3.1. Biologics Working Party (BWP)

---

Chair: Sean Barry/Francesca Luciani

Reports from BWP June 2023 meeting to CHMP for adoption:

- 13 reports on products in scientific advice and protocol assistance
- 6 reports on products in pre-authorisation procedures
- 2 reports on products in post-authorisation procedures
- 5 reports on products in plasma master file

**Action:** For adoption

The CHMP adopted the BWP reports.

### 14.3.2. Nomination of Biologics Working Party (BWP) members

---

Following the call for nominations launched in April, the BWP selection panel has recommended new BWP members.

**Action:** For endorsement

The CHMP endorsed the BWP members.

### 14.3.3. Call for nominations for BWP Chair

---

Launch call for nomination for a chair for the Biologics Working Party (BWP).

Members of BWP are invited to indicate their interest in standing for this position of chair for

---

BWP.

Applications are to be submitted before the start of the CHMP meeting on 17 July 2023.

**Action:** For information

The CHMP noted the call for nomination for a BWP chair.

#### 14.3.4. Nomination of Quality Working Party (QWP) members

---

Following the call for nominations launched in April, the QWP selection panel has recommended new QWP members.

**Action:** For endorsement

The CHMP endorsed the QWP members.

#### 14.3.5. Call for nominations for QWP Chair and Vice-chair

---

Launch call for nomination for chair and vice-chair for Quality Working Party (QWP).

Members of QWP are invited to indicate their interest in standing for this position of chair and vice-chair for QWP.

Applications are to be submitted before the start of the CHMP meeting on 17 July 2023.

**Action:** For information

The CHMP noted the call for nomination for a QWP chair and vice-chair.

#### 14.3.6. Nomination of Biosimilar Medicinal Products Working Party (BMWP) members

---

Following the call for nominations launched in April, the BMWP selection panel has recommended new BMWP members.

**Action:** For endorsement

The CHMP endorsed the BMWP members.

#### 14.3.7. Call for nominations for BMWP Chair

---

Launch call for nomination for chairs for Biosimilar Medicinal Products Working Party (BMWP).

Members of BMWP are invited to indicate their interest in standing for this position of chair for BMWP.

Applications are to be submitted before the start of the CHMP meeting on 17 July 2023.

**Action:** For information

The CHMP noted the call for nomination for a BMWP chair.

#### 14.3.8. Scientific Advice Working Party (SAWP)

---

Chair: Paolo Foggi

Report from the SAWP meeting held on 05-08 June 2023. Table of conclusions

**Action:** For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

#### 14.3.9. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus Rev. 2 – Cardiovascular Working Party (CVSWP)

---

Final Guideline

**Action:** For adoption

The CHMP adopted the guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus.

#### 14.3.10. CHMP Question to Healthcare Professionals Working Party (HCPWP)

---

CHMP questions to HCPWP on SmPC guidance section 5.1.

**Action:** For adoption

Following-up on the discussions during the Swedish Strategic Review and Learning Meeting (SRLM) on the guidance document on the information to be included in section 5.1 "Pharmacodynamic properties" of the SmPC, which also includes description of clinical trials, and given that HCPs are the primary users of the SmPC, the CHMP has drafted a LoQ to consult the HCPWP on a few specific aspects.

CHMP adopted the CHMP questions to HCPWP.

### 14.4. Cooperation within the EU regulatory network

No items

### 14.5. Cooperation with International Regulators

No items

### 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

## 14.7. CHMP work plan

No items

## 14.8. Planning and reporting

No items

## 14.9. Others

No items

# 15. Any other business

## 15.1. AOB topic

### 15.1.1. Update on COVID-19

---

**Action:** For information

The CHMP noted the information.

### 15.1.2. Control options for nitrosamines

---

**Action:** For information

The CHMP noted the update. [Post-meeting note: The Q&A was adopted by written procedure on the 7 July]

### 15.1.3. Gap analysis assessment in support of member state shortage management activities

---

**Action:** For endorsement

The Gap analysis was discussed and endorsed by CHMP.

### 15.1.4. Product Information for upcoming Comirnaty and Spikevax variant vaccine

---

Product Information for upcoming Comirnaty and Spikevax variant vaccine for preliminary discussion

**Action:** For discussion

The CHMP was informed about upcoming product information changes for the Comirnaty and Spikevax variants.



### 15.1.5. Preparation of oncology product-related discussions

---

**Action:** For discussion

Further discussion is expected at the July PROM.

### 15.1.6. Update on EMA collaborative systems

---

Update on the use of EMA collaborative systems – IRIS Network Portal, IRIS SharePoint and Teams.

**Action:** For discussion

The CHMP noted the information on using IRIS in the future for PRIME and SAWP. More specifically, information on PRIME eligibility requests and their outcome will be available on the IRIS network portal and relevant documents will be available through links to submission and case folders accessible through the same portal. Similarly, Final Advice Letters will stop being tabled in MMD but will be available through the IRIS network portal.

## List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 19-22 June 2023 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Daniela Philadelphly	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Emilia Mavrokordatou	Alternate	Cyprus	No participation in final deliberations and voting on:	COVID-19 vaccines
Tomas Radimersky	Member	Czechia	No interests declared	
Petr Vrbata	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Aaron Sosa Mejia	Alternate	Denmark	No participation in final deliberations and voting on:	Refixia - nonacog beta pegol - EMEA/H/C/004178/II/0032
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Vilma Petrikaite	Member	Lithuania	No interests declared	
Larisa Gorobets	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffer	Member	Luxembourg	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No participation in final deliberations and voting on:	Praluent - alirocumab - EMEA/H/C/0038 82/II/0078
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Andreja Kranjc	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Carolina Prieto Fernandez	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No participation in discussion, final deliberations and voting on:	Imjudo - tremelimumab - EMEA/H/C/0060 16/II/0001
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Eva Malikova	Expert	Slovakia	No interests declared	
Anna Kubandová	Expert	Slovakia	No interests declared	
Ivana Povrazníková	Expert	Slovakia	No interests declared	
Daiana Vasilcanu	Expert	Sweden	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Charlotte Anderberg	Expert	Sweden	No interests declared	
Karin Fjordén	Expert	Sweden	No participation in final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/0038 20/II/0134 EMEA/H/C/0038 20/II/0135
Karri Penttila	Expert	Finland	No interests declared	
Larissa Higgins	Expert	Ireland	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Joerg Zinserling	Expert	Germany	No interests declared	
Clemens Mittmann	Expert	Germany	No interests declared	
Anja Schiel	Expert	Norway	No interests declared	
Rune Kjekken	Expert	Norway	No restrictions applicable to this meeting	
Annette Lommel	Expert	Germany	No interests declared	
Sarah Lang	Expert	Germany	No interests declared	
Poleta Luga	Expert	Germany	No interests declared	
Claudia Heinbuecher	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Zilke Zander	Expert	Germany	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Kersti Oselin	Expert	Estonia	No participation in discussion, final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/0038 20/II/0134 EMEA/H/C/0038 20/II/0135
Vincent Gazin	Expert	France	No interests declared	
Ludivine Martin	Expert	France	No restrictions applicable to this meeting	
Natasa Sekulic	Expert	France	No interests declared	
Roxane Fornacciari	Expert	France	No interests declared	
Sargi Caizergues Lama	Expert	France	No interests declared	
Melanie Ramberger	Expert	Austria	No interests declared	
Hinke Johanna Van der Woude	Expert	Netherlands	No interests declared	
Evelien Minten	Expert	Netherlands	No interests declared	
Taco Monster	Expert	Netherlands	No interests declared	
Victoriia Starokozhko	Expert	Netherlands	No restrictions applicable to this meeting	
Quirine Fillekes	Expert	Netherlands	No interests declared	
Hester Peltenburg	Expert	Netherlands	No interests declared	
Loes den Otter	Expert	Netherlands	No interests declared	
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Carlijn Litjens	Expert	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Hanja de Kooter	Expert	Netherlands	No restrictions applicable to this meeting	
Adrian Post	Expert	Netherlands	No interests declared	
Chantal van de Schootbrugge	Expert	Netherlands	No interests declared	
Sem Runge	Expert	Netherlands	No interests declared	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Violette Dirix	Expert	Belgium	No interests declared	
Marta Romano	Expert	Belgium	No interests declared	
Edwige Haelterman Brenneisen	Expert	Belgium	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Maria Di Marzo	Expert	Italy	No interests declared	
Michaela Piezzo	Expert	Italy	No interests declared	
Ieva Rutkovska	Expert	Latvia	No interests declared	
Vita Gulevska	Expert	Latvia	No interests declared	
Diana Paegle	Expert	Latvia	No interests declared	
Kristine Moltu	Expert	Norway	No interests declared	
Fabrice Eroukhmanoff	Expert	Norway	No interests declared	
Line Praest Lauridsen	Expert	Denmark	No restrictions applicable to this meeting	
Anne-Marie Dalseg	Expert	Denmark	No interests declared	
Meera Varma	Expert	Denmark	No restrictions applicable to this meeting	
Sine Buhl Naess-Schmidt	Expert	Denmark	No restrictions applicable to this meeting	
Torsten Holm Nielsen	Expert	Denmark	No interests declared	
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Claus Stage	Expert	Denmark	No restrictions applicable to this meeting	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Ann-Cathrine Bach Dunvald	Expert	Denmark	No interests declared	
Ebru Karakoc Madsen	Expert	Denmark	No interests declared	
Kinga Nowicka-Matus	Expert	Denmark	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Katrin Buss	Expert	Germany	No interests declared	
Regine Magdalene Lehnert	Expert	Germany	No interests declared	
Tobias Siefen	Expert	Germany	No interests declared	
Lenka Kralova	Expert	Czechia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final deliberations and voting on:	Aquipta - atogepant monohydrate - EMEA/H/C/005871
Lourdes Rodriguez Rojas	Expert	Spain	No interests declared	
Maria del Pilar Rayon	Expert	Spain	No interests declared	
Eva Cantarero	Expert	Spain	No interests declared	
Veronica Garcia Gil	Expert	Spain	No interests declared	
Laura Gómez	Expert	Spain	No interests declared	
Daniel Fernández Soto	Expert	Spain	No interests declared	
Illiana Meurs	Expert	Netherlands	No interests declared	
Ismail Zor	Expert	Netherlands	No interests declared	
Charlotta Bergquist	Expert	Sweden	No interests declared	
Susanne Brendler-Schwaab	Expert	Germany	No interests declared	
Ana Moreno Oliver	Expert	Spain	No interests declared	
Marianne Depreter	Expert	Belgium	No interests declared	
Leon van Aerts	Expert	Netherlands	No interests declared	
Marianne Schmidt	Expert	Denmark	No interests declared	
Priscilla Schoondermark	Expert	Netherlands	No interests declared	
Sinead Harrington	Expert	Ireland	No interests declared	
Martijn van Gils	Expert	Netherlands	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with the help of EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

## Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

### Oral explanations (section 2)


The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

### Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

### **Extension of marketing authorisations according to Annex I of Reg. 1234/2008** (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

### **Type II variations - Extension of indication procedures** (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

### **Ancillary medicinal substances in medical devices** (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

### **Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

### **Re-examination procedures** (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

### **Withdrawal of application** (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

### **Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

### **Pre-submission issues** (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

### **Post-authorisation issues** (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.



### **Referral procedures** (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

### **Pharmacovigilance issues** (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

### **Inspections Issues** (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

### **Innovation task force** (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

### **Scientific advice working party (SAWP)** (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

### **Satellite groups / other committees** (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

### **Invented name issues** (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)



06 September 2023  
EMA/CHMP/282646/2023

## Annex to 19-22 June 2023 CHMP Minutes

### Pre-submission and post-authorisations issues

<b>A. PRE-SUBMISSION ISSUES .....</b>	<b>3</b>
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications .....	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION .....	3
<b>B. POST-AUTHORISATION PROCEDURES OUTCOMES .....</b>	<b>3</b>
B.1. Annual re-assessment outcomes.....	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances .....	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES .....	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal.....	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity .....	4
B.2.3. Renewals of Conditional Marketing Authorisations .....	5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES .....	6
B.4. EPARs / WPARs .....	11
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES .....	12
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects .....	12
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .....	16
B.5.3. CHMP-PRAC assessed procedures.....	29
B.5.4. PRAC assessed procedures.....	36
B.5.5. CHMP-CAT assessed procedures .....	41
B.5.6. CHMP-PRAC-CAT assessed procedures.....	43
B.5.7. PRAC assessed ATMP procedures .....	43
B.5.8. Unclassified procedures and worksharing procedures of type I variations .....	43
B.5.9. Information on withdrawn type II variation / WS procedure .....	46
B.5.10. Information on type II variation / WS procedure with revised timetable .....	46
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION .....	46
B.6.1. Start of procedure for New Applications: timetables for information .....	46
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .....	47



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information .....	48
B.6.4. Annual Re-assessments: timetables for adoption.....	48
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed .....	48
B.6.6. VARIATIONS – START OF THE PROCEDURE .....	49
B.6.7. Type II Variations scope of the Variations: Extension of indication .....	49
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .....	53
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	53
B.6.10. CHMP-PRAC assessed procedures.....	53
B.6.11. PRAC assessed procedures .....	53
B.6.12. CHMP-CAT assessed procedures.....	53
B.6.13. CHMP-PRAC-CAT assessed procedures .....	54
B.6.14. PRAC assessed ATMP procedures.....	54
B.6.15. Unclassified procedures and worksharing procedures of type I variations .....	54
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY .....	54
B.7.1. Yearly Line listing for Type I and II variations .....	54
B.7.2. Monthly Line listing for Type I variations .....	54
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .....	54
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only).....	54
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only).....	54
B.7.6. Notifications of Type I Variations (MMD only).....	54
<b>C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) .....</b>	<b>54</b>
<b>D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) .....</b>	<b>54</b>
<b>E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES .....</b>	<b>54</b>
E.1. PMF Certification Dossiers:.....	55
E.1.1. Annual Update .....	55
E.1.2. Variations:.....	55
E.1.3. Initial PMF Certification:.....	55
E.2. Time Tables – starting & ongoing procedures: For information .....	55
<b>F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver ....</b>	<b>55</b>
F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended .....	55
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health .....	55
<b>G. ANNEX G.....</b>	<b>55</b>
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .....	55
G.2. PRIME .....	55
G.2.1. List of procedures concluding at 19-22 June 2023 CHMP plenary .....	55

## H. ANNEX H - Product Shared Mailboxes – e-mail address ..... 55

### A. PRE-SUBMISSION ISSUES

#### A.1. ELIGIBILITY REQUESTS

---

Report on Eligibility to Centralised Procedure for June 2023: <b>For adoption</b>	Adopted
--	---------

---

#### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

---

Final Outcome of Rapporteurship allocation for June 2023: <b>For adoption</b>	Adopted
--	---------

---

#### A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

### B. POST-AUTHORISATION PROCEDURES OUTCOMES

#### B.1. Annual re-assessment outcomes

##### B.1.1. Annual reassessment for products authorised under exceptional circumstances

---

<b>Evoltra - clofarabine - EMA/H/C/000613/S/0078</b> Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.
<b>Lamzede - velmanase alfa - EMA/H/C/003922/S/0031, Orphan</b> Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.
<b>SCENESSE - afamelanotide - EMA/H/C/002548/S/0045, Orphan</b> Clinivel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 26.04.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.

---

## B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

### B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

### B.2.2. Renewals of Marketing Authorisations for unlimited validity

<p><b>Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/R/0027</b> Sanofi Pasteur, Rapporteur: Christophe Focke, Co-Rapporteur: Sol Ruiz, PRAC Rapporteur: Sonja Hrabcik</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/R/0038</b> Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted on 22.06.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Lenalidomide Accord - lenalidomide - EMEA/H/C/004857/R/0021</b> Accord Healthcare S.L.U., Generic, Generic of Revlimid, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 26.04.2023.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Namuscla - mexiletine - EMEA/H/C/004584/R/0014, Orphan</b> Lupin Europe GmbH, Rapporteur: Bruno Sepodes, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva Jirsová</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Ogivri - trastuzumab - EMEA/H/C/004916/R/0054</b> Viartis Limited, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p><b>Pelmeg - pegfilgrastim - EMEA/H/C/004700/R/0025</b> Mundipharma Corporation (Ireland) Limited,</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

---

Rapporteur: Karin Janssen van Doorn, Co-  
Rapporteur: Christian Gartner, PRAC  
Rapporteur: Menno van der Elst  
Request for Supplementary Information adopted  
on 22.06.2023.

---

**POTELIGEO - mogamulizumab -  
EMA/H/C/004232/R/0021, Orphan**  
Kyowa Kirin Holdings B.V., Rapporteur: Johann  
Lodewijk Hillege, Co-Rapporteur: Armando  
Genazzani, PRAC Rapporteur: Marie Louise  
Schougaard Christiansen

Positive Opinion adopted by consensus together  
with the CHMP assessment report and  
translation timetable.

Based on the review of the available  
information, the CHMP was of the opinion that  
the renewal of the marketing authorisation can  
be granted with unlimited validity.

---

**Symkevi - tezacaftor / ivacaftor -  
EMA/H/C/004682/R/0038, Orphan**  
Vertex Pharmaceuticals (Ireland) Limited,  
Rapporteur: Johann Lodewijk Hillege, Co-  
Rapporteur: Beata Maria Jakline Ullrich, PRAC  
Rapporteur: Rhea Fitzgerald  
Request for Supplementary Information adopted  
on 30.03.2023.

Positive Opinion adopted by consensus together  
with the CHMP assessment report and  
translation timetable.

Based on the review of the available  
information, the CHMP was of the opinion that  
the renewal of the marketing authorisation can  
be granted with unlimited validity.

---

**TAKHZYRO - lanadelumab -  
EMA/H/C/004806/R/0035, Orphan**  
Takeda Pharmaceuticals International AG  
Ireland Branch, Rapporteur: Kristina Dunder,  
Co-Rapporteur: Jean-Michel Race, PRAC  
Rapporteur: Kirsti Villikka  
Request for Supplementary Information adopted  
on 25.05.2023.

Positive Opinion adopted by consensus together  
with the CHMP assessment report and  
translation timetable.

Based on the review of the available  
information, the CHMP was of the opinion that  
the renewal of the marketing authorisation can  
be granted with unlimited validity.

---

**Venclyxto - venetoclax -  
EMA/H/C/004106/R/0046**  
AbbVie Deutschland GmbH & Co. KG,  
Rapporteur: Filip Josephson, Co-Rapporteur:  
Johann Lodewijk Hillege, PRAC Rapporteur: Eva  
Jirsová  
Request for Supplementary Information adopted  
on 26.04.2023.

Positive Opinion adopted by consensus together  
with the CHMP assessment report.

Based on the review of the available  
information, the CHMP was of the opinion that  
the renewal of the marketing authorisation can  
be granted with unlimited validity.

---

### **B.2.3. Renewals of Conditional Marketing Authorisations**

---

**Adakveo - crizanlizumab -  
EMA/H/C/004874/R/0014, Orphan**  
Novartis Europharm Limited, Rapporteur:  
Daniela Philadelph, PRAC Rapporteur: Jo  
Robays

Postponed in light of the article 20 referral on  
Adakveo EMA/H/A-20/1525.

(see May 2023 minutes)

---

**Blenrep - belantamab mafodotin -  
EMA/H/C/004935/R/0017, Orphan**  
GlaxoSmithKline (Ireland) Limited, Rapporteur:

Request for supplementary information adopted  
with a specific timetable.

---

---

Johanna Lähtenvuo, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Ulla Wändel Liminga  
Request for Supplementary Information adopted on 26.04.2023.

---

### **B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES**

---

#### **Signal detection**

PRAC recommendations on signals adopted at the PRAC meeting held on 05-08 June 2023  
PRAC:

---

#### **Signal of cytokine release syndrome**

The CHMP adopted the PRAC recommendation.

Opdivo (CAP) – nivolumab

(please note this is part of the signal of Ipilimumab; nivolumab; pembrolizumab – Capillary leak syndrome (Opdivo, Yervoy, Keytruda) and cytokine release syndrome (Opdivo) – EPITT 19880)

Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

PRAC recommendation on a variation

**Action:** For adoption

---

#### **Signal of acnes**

The CHMP adopted the PRAC recommendation.

Xeljanz (CAP) – tofacitinib

Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

PRAC recommendation on a variation

**Action:** For adoption

---

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its June 2023 meeting:

---

---

**EMA/H/C/PSUSA/00001069/202210**

(artenimol / piperazine tetraphosphate)

CAPS:

**Eurartesim** (EMA/H/C/001199) (piperazine tetraphosphate / artenimol), Alfasigma S.p.A.,

Rapporteur: Janet Koenig, PRAC Rapporteur:

Martin Huber, "27/10/2019 To: 27/10/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction "hepatocellular injury" with a frequency uncommon. The package leaflet is updated accordingly.

Only the ADR table(s) reflecting information for the adult population should be updated.

---

**EMA/H/C/PSUSA/00001172/202211**

(doxorubicin)

CAPS:

**Caelyx pegylated liposomal**

(EMA/H/C/000089) (doxorubicin), Baxter Holding B.V., Rapporteur: Petr Vrbata

**Celdoxome pegylated liposomal**

(EMA/H/C/005330) (doxorubicin), YES Pharmaceutical Development Services GmbH, Rapporteur: Fátima Ventura

**Myocet liposomal** (EMA/H/C/000297)

(doxorubicin hydrochloride), Teva B.V., Rapporteur: Filip Josephson

**Zolsketil pegylated liposomal**

(EMA/H/C/005320) (doxorubicin), Accord Healthcare S.L.U., Rapporteur: Carolina Prieto Fernandez

NAPS:

**NAPs** - EU

PRAC Rapporteur: Eva Jirsová, "12/11/2021

To: 12/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add a warning regarding interstitial lung disease and the adverse reaction interstitial lung disease with a frequency not known. The package leaflet is updated accordingly.



---

**EMA/H/C/PSUSA/00002652/202211**

(rituximab)

CAPS:

**Blitzima** (EMA/H/C/004723) (rituximab),  
Celltrion Healthcare Hungary Kft., Rapporteur:  
Sol Ruiz

**MabThera** (EMA/H/C/000165) (rituximab),  
Roche Registration GmbH, Rapporteur: Aaron  
Sosa Mejia

**Rixathon** (EMA/H/C/003903) (rituximab),  
Sandoz GmbH, Rapporteur: Jan Mueller-  
Berghaus

**Riximyo** (EMA/H/C/004729) (rituximab),  
Sandoz GmbH, Rapporteur: Jan Mueller-  
Berghaus

**Ruxience** (EMA/H/C/004696) (rituximab),  
Pfizer Europe MA EEIG, Rapporteur: Johann  
Lodewijk Hillege

**Truxima** (EMA/H/C/004112) (rituximab),  
Celltrion Healthcare Hungary Kft., Rapporteur:  
Sol Ruiz, PRAC Rapporteur: Marie Louise  
Schougaard Christiansen, "17/11/2021 To:  
17/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add a warning/precaution regarding enteroviral meningoencephalitis and to add the adverse reaction enteroviral meningoencephalitis with a frequency Not known. The Package leaflet is updated accordingly.

Update of section 4.4 of the SmPC to add a warning/precaution regarding the possibility of false negative serologic testing of infections. This update is not considered warranted in the PIL.

---

**EMA/H/C/PSUSA/00002841/202210**

(tadalafil)

CAPS:

**Adcirca** (EMA/H/C/001021) (tadalafil), Eli Lilly Nederland B.V., Rapporteur: Maria Concepcion Prieto Yerro

**Cialis** (EMA/H/C/000436) (tadalafil), Eli Lilly Nederland B.V., Rapporteur: Maria Concepcion Prieto Yerro

**Tadalafil Lilly** (EMA/H/C/004666)  
(tadalafil), Eli Lilly Nederland B.V.,  
Rapporteur: Maria Concepcion Prieto Yerro  
NAPS:

**NAPs** - EU

PRAC Rapporteur: Maria del Pilar Rayon,  
"14/10/2019 To: 14/10/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add information about central serous chorioretinopathy.

---

**EMA/H/C/PSUSA/0009176/202211**  
(hydrocortisone (for centrally authorised products for adrenal insufficiency, congenital adrenal hyperplasia, modified-release formulations))

CAPS:

**Efmody** (EMA/H/C/005105)  
(hydrocortisone), Diurnal Europe BV,  
Rapporteur: Johann Lodewijk Hillege  
**Plenadren** (EMA/H/C/002185)  
(hydrocortisone), Takeda Pharmaceuticals  
International AG Ireland Branch, Rapporteur:  
Kristina Dunder, PRAC Rapporteur: Mari  
Thorn, "02/11/2019 To: 02/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus:

- the variation to the terms of the marketing authorisation(s) for the medicinal product Efmody, concerning the following change(s):  
Update of sections 4.4 and 4.6 of the SmPC to add a precaution regarding unexpected early improvement of infertility (4.4) and delete information regarding fertility (4.6).
- the maintenance of the terms of the Marketing Authorisation for the medicinal product Plenadren.

---

**EMA/H/C/PSUSA/00010301/202211**  
(ibrutinib)

CAPS:

**Imbruvica** (EMA/H/C/003791) (ibrutinib),  
Janssen-Cilag International N.V., Rapporteur:  
Filip Josephson, PRAC Rapporteur: Nikica  
Mirošević Skvrce, "13/11/2021 To:  
12/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction Acute kidney injury with a frequency common and to add the adverse reaction Pyogenic granuloma with a frequency uncommon. The Package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00010318/202210**  
(nintedanib (oncology indications))

CAPS:

**Vargatef** (EMA/H/C/002569) (nintedanib),  
Boehringer Ingelheim International GmbH,  
Rapporteur: Aaron Sosa Mejia, PRAC  
Rapporteur: Georgia Gkegka, "15/10/2019 To:  
15/10/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to amend a warning/precaution regarding gastrointestinal perforations and ischaemic colitis. The package leaflet is updated accordingly.

---

---

**EMA/H/C/PSUSA/00010887/202210**

(acalabrutinib)

CAPS:

**Calquence** (EMA/H/C/005299)

(acalabrutinib), AstraZeneca AB, Rapporteur:  
Filip Josephson, PRAC Rapporteur: Željana  
Margan Koletić, "31/10/2021 To: 30/10/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction hypertension with frequencies common and very common for acalabrutinib monotherapy and combination therapy respectively. The package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00010917/202211**

(selpercatinib)

CAPS:

**Retsevmo** (EMA/H/C/005375)

(selpercatinib), Eli Lilly Nederland B.V.,  
Rapporteur: Alexandre Moreau, PRAC  
Rapporteur: Menno van der Elst, "08/05/2022  
To: 08/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.4, 4.5 and 4.8 of the SmPC to add the adverse reaction hypothyroidism with a frequency very common, including a warning/precaution regarding relevant monitoring requirements. The package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00010992/202211**

(tixagevimab / cilgavimab (Evusheld))

CAPS:

**EVUSHELD** (EMA/H/C/005788) (tixagevimab

/ cilgavimab), AstraZeneca AB, Rapporteur:  
Jan Mueller-Berghaus, PRAC Rapporteur:  
Kimmo Jaakkola, "14/05/2022 To:  
13/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction anaphylaxis with a frequency "rare". The package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/00011019/202211**

(tirzepatide)

CAPS:

**Mounjaro** (EMA/H/C/005620) (tirzepatide),  
Eli Lilly Nederland B.V., Rapporteur: Martina  
Weise, PRAC Rapporteur: Menno van der Elst,  
"13/05/2022 To: 13/11/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of section 4.8 of the SmPC to add the adverse reaction injection site pain to the summary table with a frequency uncommon.  
The package leaflet is updated accordingly.

---

**B.4. EPARs / WPARs**

---

**Briumvi - ublituximab - EMA/H/C/005914**

Propharma Group The Netherlands B.V.,  
treatment of relapsing forms of multiple  
sclerosis (RMS), New active substance (Article  
8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Pylclari - piflufolastat (18f) -****EMA/H/C/005520**

Curium Pet France, imaging in patients  
undergoing oncologic diagnostic procedures  
when increased expression of prostate specific  
membrane antigen is a diagnostic target, New  
active substance (Article 8(3) of Directive No  
2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Qaialdo - spironolactone -****EMA/H/C/005535**

Nova Laboratories Ireland Limited, management  
of refractory oedema, Hybrid application (Article  
10(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**SOHONOS - palovarotene -****EMA/H/C/004867, Orphan**

Ipsen Pharma, treatment of fibrodysplasia  
ossificans progressiva, New active substance  
(Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Sugammadex Piramal - sugammadex -****EMA/H/C/006083**

Piramal Critical Care B.V., Reversal of  
neuromuscular blockade induced by rocuronium  
or vecuronium in adults, Generic, Generic of  
Bridion, Generic application (Article 10(1) of  
Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

---

**Ztalmy - ganaxolone - EMA/H/C/005825,  
Orphan**

For information only. Comments can be sent to

---

---

Marinus Pharmaceuticals Emerald Limited, the PL in case necessary.  
treatment of epileptic seizures associated with  
cyclindependent kinase-like 5 deficiency  
disorder (CDD), New active substance (Article  
8(3) of Directive No 2001/83/EC)

---

## **B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES**

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

### **B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects**

---

**Advate - octocog alfa -** Positive Opinion adopted by consensus on  
**EMA/H/C/000520/II/0120/G** 22.06.2023.

Takeda Manufacturing Austria AG, Rapporteur:  
Jan Mueller-Berghaus  
Opinion adopted on 22.06.2023.

---

**Aflunov - prepandemic influenza vaccine** Request for supplementary information adopted  
**(H5N1) (surface antigen, inactivated,** with a specific timetable.  
**adjuvanted) -**

**EMA/H/C/002094/II/0084/G**  
Seqirus S.r.l, Rapporteur: Maria Grazia Evandri  
Request for Supplementary Information adopted  
on 22.06.2023.

---

**Apexxnar - pneumococcal polysaccharide** Positive Opinion adopted by consensus on  
**conjugate vaccine (20-valent, adsorbed) -** 01.06.2023.  
**EMA/H/C/005451/II/0014/G**

Pfizer Europe MA EEIG, Rapporteur: Daniela  
Philadelphia  
Opinion adopted on 01.06.2023.

---

**Azacitidine betapharm - azacitidine -** Request for supplementary information adopted  
**EMA/H/C/005075/II/0015** with a specific timetable.

betapharm Arzneimittel GmbH, Generic, Generic  
of Vidaza, Rapporteur: Petr Vrbata  
Request for Supplementary Information adopted  
on 15.06.2023.

---

**Azacitidine betapharm - azacitidine -** Request for supplementary information adopted  
**EMA/H/C/005075/II/0016** with a specific timetable.

betapharm Arzneimittel GmbH, Generic, Generic  
of Vidaza, Rapporteur: Petr Vrbata  
Request for Supplementary Information adopted  
on 22.06.2023.

---

**Brintellix - vortioxetine -** Positive Opinion adopted by consensus on  
**EMA/H/C/002717/II/0033** 15.06.2023.

H. Lundbeck A/S, Rapporteur: Karin Janssen  
van Doorn  
Opinion adopted on 15.06.2023.

---

---

Request for Supplementary Information adopted on 01.12.2022, 02.06.2022.

---

**COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0178** Positive Opinion adopted by consensus on 01.06.2023.  
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson  
Opinion adopted on 01.06.2023.

---

**COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0181** Positive Opinion adopted by consensus on 22.06.2023.  
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson  
Opinion adopted on 22.06.2023.

---

**COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0182/G** Positive Opinion adopted by consensus on 22.06.2023.  
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson  
Opinion adopted on 22.06.2023.

---

**ECALTA - anidulafungin - EMEA/H/C/000788/II/0052/G** Positive Opinion adopted by consensus on 08.06.2023.  
Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege  
Opinion adopted on 08.06.2023.  
Request for Supplementary Information adopted on 16.02.2023.

---

**Epidyolex - cannabidiol - EMEA/H/C/004675/II/0025/G, Orphan** Positive Opinion adopted by consensus on 01.06.2023.  
Jazz Pharmaceuticals Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher  
Opinion adopted on 01.06.2023.  
Request for Supplementary Information adopted on 23.03.2023.

---

**Eptifibatide Accord - eptifibatide - EMEA/H/C/004104/II/0016/G** Positive Opinion adopted by consensus on 08.06.2023.  
Accord Healthcare S.L.U., Generic, Generic of Integrilin, Rapporteur: Jayne Crowe  
Opinion adopted on 08.06.2023.  
Request for Supplementary Information adopted on 04.05.2023.

---

**Eylea - aflibercept - EMEA/H/C/002392/II/0086** Positive Opinion adopted by consensus on 01.06.2023.  
Bayer AG, Rapporteur: Alexandre Moreau  
Opinion adopted on 01.06.2023.

---

**Gazyvaro - obinutuzumab -** Request for supplementary information adopted

---

<p><b>EMEA/H/C/002799/II/0053/G, Orphan</b>  Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia  Request for Supplementary Information adopted on 22.06.2023.</p>	with a specific timetable.
<p><b>Idacio - adalimumab - EMEA/H/C/004475/II/0018/G</b>  Fresenius Kabi Deutschland GmbH, Rapporteur: Johann Lodewijk Hillege  Opinion adopted on 15.06.2023.  Request for Supplementary Information adopted on 23.03.2023.</p>	Positive Opinion adopted by consensus on 15.06.2023.
<p><b>LIVMARLI - maralixibat - EMEA/H/C/005857/II/0002, Orphan</b>  Mirum Pharmaceuticals International B.V., Rapporteur: Martina Weise  Opinion adopted on 15.06.2023.</p>	Positive Opinion adopted by consensus on 15.06.2023.
<p><b>Lonsurf - trifluridine / tipiracil - EMEA/H/C/003897/II/0025</b>  Les Laboratoires Servier, Rapporteur: Johann Lodewijk Hillege  Opinion adopted on 15.06.2023.  Request for Supplementary Information adopted on 19.01.2023.</p>	Positive Opinion adopted by consensus on 15.06.2023.
<p><b>Ontruzant - trastuzumab - EMEA/H/C/004323/II/0046/G</b>  Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn  Opinion adopted on 15.06.2023.</p>	Positive Opinion adopted by consensus on 15.06.2023.
<p><b>Pluvicto - lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483/II/0003</b>  Novartis Europharm Limited, Rapporteur: Janet Koenig  Request for Supplementary Information adopted on 01.06.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p><b>POTELIGEO - mogamulizumab - EMEA/H/C/004232/II/0020, Orphan</b>  Kyowa Kirin Holdings B.V., Rapporteur: Johann Lodewijk Hillege  Request for Supplementary Information adopted on 22.06.2023, 14.04.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p><b>Roclanda - latanoprost / netarsudil - EMEA/H/C/005107/II/0011</b>  Santen Oy, Rapporteur: Jayne Crowe  Opinion adopted on 01.06.2023.  Request for Supplementary Information adopted</p>	Positive Opinion adopted by consensus on 01.06.2023.

---

on 09.02.2023.

---

**Spikevax - COVID-19 mRNA vaccine  
(nucleoside-modified) -  
EMA/H/C/005791/II/0100/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan  
Mueller-Berghaus  
Request for Supplementary Information adopted  
on 15.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**Supemtek - influenza quadrivalent vaccine  
(rDNA) - EMA/H/C/005159/II/0011/G**

Sanofi Pasteur, Rapporteur: Jan Mueller-  
Berghaus  
Request for Supplementary Information adopted  
on 08.06.2023, 09.02.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**Surgiflo Haemostatic Matrix Kit - human  
thrombin - EMA/H/D/002301/II/0034/G**

Ferrosan Medical Devices A/S, Rapporteur: Jan  
Mueller-Berghaus  
Opinion adopted on 15.06.2023.

Positive Opinion adopted by consensus on  
15.06.2023.

---

**TOBI Podhaler - tobramycin -  
EMA/H/C/002155/II/0057/G, Orphan**

Viatrix Healthcare Limited, Rapporteur: Johann  
Lodewijk Hillege  
Request for Supplementary Information adopted  
on 15.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**Toujeo - insulin glargine -  
EMA/H/C/000309/II/0121/G**

Sanofi-Aventis Deutschland GmbH, Duplicate,  
Duplicate of Lantus, Rapporteur: Johann  
Lodewijk Hillege  
Opinion adopted on 22.06.2023.

Positive Opinion adopted by consensus on  
22.06.2023.

---

**TRODELVY - sacituzumab govitecan -  
EMA/H/C/005182/II/0023/G**

Gilead Sciences Ireland UC, Rapporteur: Jan  
Mueller-Berghaus  
Request for Supplementary Information adopted  
on 08.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**TRODELVY - sacituzumab govitecan -  
EMA/H/C/005182/II/0024/G**

Gilead Sciences Ireland UC, Rapporteur: Jan  
Mueller-Berghaus  
Request for Supplementary Information adopted  
on 08.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**Vaxelis - diphtheria, tetanus, pertussis  
(acellular, component), hepatitis B (rDNA),  
poliomyelitis (inact.) and haemophilus type**

Positive Opinion adopted by consensus on  
08.06.2023.

---



---

**B conjugate vaccine (adsorbed) -****EMA/H/C/003982/II/0119/G**

MCM Vaccine B.V., Rapporteur: Christophe

Focke

Opinion adopted on 08.06.2023.

---

**VidPrevtn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant - EMA/H/C/005754/II/0003**

Sanofi Pasteur, Rapporteur: Jan Mueller-

Berghaus

Request for Supplementary Information adopted

on 01.06.2023.

Request for supplementary information adopted with a specific timetable.

---

**Zinplava - bezlotoxumab -****EMA/H/C/004136/II/0038/G**

Merck Sharp &amp; Dohme B.V., Rapporteur: Jan

Mueller-Berghaus

Opinion adopted on 22.06.2023.

Positive Opinion adopted by consensus on 22.06.2023.

---

**WS2479****Hexacima-****EMA/H/C/002702/WS2479/0146****Hexyon-****EMA/H/C/002796/WS2479/0150**

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-

Berghaus

Opinion adopted on 08.06.2023.

Positive Opinion adopted by consensus on 08.06.2023.

---

**B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Adtralza - tralokinumab -****EMA/H/C/005255/II/0008**

LEO Pharma A/S, Rapporteur: Jayne Crowe, "To update section 4.8 of the SmPC in order to update safety information based on interim results from the ECZTEND study, listed as a category 3 study in the RMP. This is a phase 3 open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with moderate-to-severe atopic dermatitis who participated in previous tralokinumab clinical trials.

In addition, the MAH is taking this opportunity to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 01.06.2023, 09.02.2023.

Request for supplementary information adopted with a specific timetable.

---

**Aimovig - erenumab -****EMA/H/C/004447/II/0026/G**

Positive Opinion adopted by consensus on 15.06.2023.

---

Novartis Europharm Limited, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update clinical efficacy and safety information based on final results from studies CAMG334A2301 (LIBERTY) and CAMG334ADE01 (HER-MES). The 'LIBERTY' study is a randomized, double-blind, parallel-group, placebo-controlled phase 3 study to assess the efficacy and tolerability of Aimovig in adult patients with episodic migraine who had previously failed 2- 4 prophylactic migraine treatments, while the 'HER-MES' study is a randomized, double-blind, double-dummy, multicenter, parallel group, phase 4 study to assess tolerability and efficacy of Aimovig against topiramate in adult patients with episodic and chronic migraine."

Opinion adopted on 15.06.2023.

Request for Supplementary Information adopted on 12.05.2023.

---

**Brintellix - vortioxetine -  
EMA/H/C/002717/II/0038**

H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to include clinically relevant information on the efficacy, safety, tolerability, and PK of vortioxetine in the paediatric population based on final results from studies 12709A, 12712A and 12712B.

Study 12709A is an interventional, randomized, double-blind, placebo-controlled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) to evaluate efficacy and safety. Whereas studies 12712A and 12712B are 2 open-label, long-term safety and efficacy studies in children and adolescents: one 6-month extension study (study 12712A) to studies 12709A and 12710A, and one 18-month extension study (study 12712B) to study 12712A. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023, 15.12.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**CABOMETYX - cabozantinib -  
EMA/H/C/004163/II/0032**

Ipsen Pharma, Rapporteur: Ingrid Wang, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vanishing Bile

Positive Opinion adopted by consensus on 08.06.2023.

---

Duct Syndrome (VBDS), to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon and to add vanishing bile duct syndrome to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the global safety database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”  
Opinion adopted on 08.06.2023.

---

**Dupixent - dupilumab -  
EMA/H/C/004390/II/0071**

Positive Opinion adopted by consensus on  
15.06.2023.

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC in order to support the longer-term (5-year) safety of dupilumab in adults with moderate-to-severe Atopic Dermatitis (AD) based on final results from study R668-AD-1225 listed as a specific PASS category 3 study in the RMP.  
The study R668-AD-1225 was a phase 3, multicenter, open-label extension (OLE) study of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) who had previously participated in dupilumab clinical trials. The main objective of this study is to assess the long-term safety of dupilumab administered in adult patients with AD.”  
Opinion adopted on 15.06.2023.

---

**Dupixent - dupilumab -  
EMA/H/C/004390/II/0072**

Request for supplementary information adopted  
with a specific timetable.

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update the safety and efficacy information relevant to patients with hand and foot Atopic Dermatitis based on the results from study R668-AD-1924. This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis.”  
Request for Supplementary Information adopted on 22.06.2023.

---

**Invokana - canagliflozin -  
EMA/H/C/002649/II/0062**

Positive Opinion adopted by consensus on  
15.06.2023.

Janssen-Cilag International N.V., Rapporteur:

---

---

Martina Weise, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information with lithium, based on a safety review. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Opinion adopted on 15.06.2023.

Request for Supplementary Information adopted on 14.04.2023.

---

**Kanuma - sebelipase alfa -  
EMA/H/C/004004/II/0044, Orphan**

Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2 and 6.6 of the SmPC in order to limit the 1-hour infusion time only to those patients receiving the 1 mg/kg dose and to modify the table for 'recommended infusion volumes' to address the USP endotoxin limit. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Opinion adopted on 22.06.2023.

Positive Opinion adopted by consensus on 22.06.2023.

---

**Kisqali - ribociclib -  
EMA/H/C/004213/II/0041/G**

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Grouped application comprising two type II variations as follows:

- Update of section 5.2 of the SmPC in order to update absorption information based on final results from study CLEE011A2117, a Phase I, single center, two-period, two-treatment, open label, randomized crossover study to investigate the absolute bioavailability of a single oral dose of 600 mg of ribociclib relative to an intravenous (i.v.) infusion of 150 mg ribociclib in healthy subjects.

- Update of sections 4.2 and 4.5 of the SmPC in order to update the recommended dose modification when ribociclib is administered in combination with CYP3A4 inhibitors and update the drug-drug interaction information on substances that may increase ribociclib plasma concentrations based on the updated PBPK modelling.

In addition, the MAH took this opportunity to introduce minor editorial changes to the Package Leaflet."

Request for Supplementary Information adopted on 22.06.2023.

---

Request for supplementary information adopted with a specific timetable.

---

---

**Koselugo - selumetinib -  
EMA/H/C/005244/II/0013, Orphan**

AstraZeneca AB, Rapporteur: Alexandre Moreau,  
"Update of sections 4.2 and 5.2 of the SmPC in order to update the recommended dosage regimen to remove the fasting state and update pharmacokinetic information, based on the final results from study D1346C00015; this is a phase 1, single-arm, sequential study to evaluate the effect of food on the gastrointestinal tolerability and pharmacokinetics of selumetinib after multiple doses in adolescent children with neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PN). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Request for Supplementary Information adopted on 22.06.2023.

Request for supplementary information adopted with a specific timetable.

---

**Nexviadyme - avalglucosidase alfa -  
EMA/H/C/005501/II/0008**

Sanofi B.V., Rapporteur: Christian Gartner,  
"Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the list of adverse drug reactions (ADRs) and to update the safety and efficacy information, based on interim results from the open-label extension period of study EFC14028 as well as pooled safety and immunogenicity data. EFC14028 is a phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of avalglucosidase alfa and alglucosidase alfa in treatment naïve patients with late-onset Pompe disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Request for Supplementary Information adopted on 08.06.2023.

Request for supplementary information adopted with a specific timetable.

---

**NUVAXOVID - covid-19 vaccine  
(recombinant, adjuvanted) -  
EMA/H/C/005808/II/0030**

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Submission of 6-month efficacy and safety interim data from the ongoing randomized, observer-blinded, placebo-controlled clinical studies 2019nCoV-501,

Request for supplementary information adopted with a specific timetable.

---

2019nCoV-301 and 2019nCoV-302.”  
Request for Supplementary Information adopted  
on 22.06.2023, 15.12.2022.

---

**Orgovyx - relugolix -  
EMA/H/C/005353/II/0012**

Accord Healthcare S.L.U., Rapporteur: Johann  
Lodewijk Hillege, “Update of section 4.5 of the  
SmPC based on final results from study MVT-  
601-9039; this is an In vitro Interaction Study  
of Relugolix with human OATP2B1 Uptake  
Transporter.”

Opinion adopted on 01.06.2023.

Positive Opinion adopted by consensus on  
01.06.2023.

---

**Paxlovid - nirmatrelvir / ritonavir -  
EMA/H/C/005973/II/0040/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel  
Race, “Grouped application comprising two type  
II variations as follows:

- Update of section 4.3 of the SmPC in order to  
add ‘Mineralocorticoid receptor antagonists:  
finerenone’ and ‘Opioid antagonists: naloxegol’  
under Medicinal products that are highly  
dependent on CYP3A for clearance and for which  
elevated plasma concentrations are associated  
with serious and/or life-threatening reactions  
and to add ‘primidone’ and ‘Cystic fibrosis  
transmembrane conductance regulator  
potentiators: lumacaftor/ivacaftor’ under  
Medicinal products that are potent CYP3A  
inducers where significantly reduced  
nirmatrelvir/ritonavir plasma concentrations  
may be associated with the potential for loss of  
virologic response and possible resistance based  
on the review of the PI for a number of  
medicines from different drug classes that are  
metabolised by CYP3A4 or CYP2D6, transported  
by P-gp, or induce CYP3A4.
  - Update of section 4.5 of the SmPC in order to  
add drug-drug interaction information with  
Alpha1-adrenoreceptor antagonist, Analgesics,  
Antiarrhythmics, Anticoagulants,  
Anticonvulsants, Anti-HIV, Anti-infectives,  $\beta$ 2-  
agonist (long acting), Calcium channel  
antagonists, Cardiovascular agents and Migraine  
medicinal products, to add drug-drug interaction  
information with Cystic fibrosis transmembrane  
conductance regulator potentiators, Dipeptidyl  
peptidase 4 (DPP4) inhibitors, Janus kinase  
(JAK) inhibitors, Mineralocorticoid receptor  
antagonists, Muscarinic receptor antagonists,
- 

Request for supplementary information adopted  
with a specific timetable.

---

---

Neuropsychiatric agents and Opioid antagonists and in order to remove cross reference to section 4.4 from information regarding coadministration of Paxlovid with Antidepressants based on the review of the PI for a number of medicines from different drug classes that are metabolised by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4.”

Request for Supplementary Information adopted on 22.06.2023.

---

**Reblozyl - luspaterecept -  
EMA/H/C/004444/II/0016, Orphan**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphia, “Update of section 5.1 of the SmPC in order to reflect the correct values of late-reported transfusions and modifications of previously reported transfusions based on final results from study ACE-536-B-THAL-001 (BELIEVE), A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspaterecept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta-Thalassemia.”

Opinion adopted on 15.06.2023.

Request for Supplementary Information adopted on 16.03.2023.

Positive Opinion adopted by consensus on 15.06.2023.

---

**RINVOQ - upadacitinib -  
EMA/H/C/004760/II/0034**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, “Submission of the final report from study M13-542, listed as a category 3 study in the RMP. This is a phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) to placebo on stable conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) in subjects with moderately to severely active rheumatoid arthritis with inadequate response or intolerance to biologic DMARDs (bDMARDs).”

Request for Supplementary Information adopted on 08.06.2023.

Request for supplementary information adopted with a specific timetable.

---

**RINVOQ - upadacitinib -  
EMA/H/C/004760/II/0035**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, “Submission of the final report from study M13-549 listed as a category 3 study in the RMP. This is a Phase III,

Request for supplementary information adopted with a specific timetable.

---

Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs.”  
Request for Supplementary Information adopted on 08.06.2023.

---

**Rydapt - midostaurin -  
EMA/H/C/004095/II/0029, Orphan**

Positive Opinion adopted by consensus on 22.06.2023.

Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.8 of the SmPC in order to add “Acute febrile neutrophilic dermatosis” to the list of adverse drug reactions (ADRs) with frequency not known based on pre-clinical data, clinical trial datasets, scientific literature and safety databases. The Package Leaflet is updated accordingly. The MAH took the occasion to also include some editorial/formatting changes in the product information. The MAH has also taken the occasion to align the annex A to the correct expression of pack size as included in the registered system (Siamed).”  
Opinion adopted on 22.06.2023.  
Request for Supplementary Information adopted on 30.03.2023.

---

**Scemblix - asciminib -  
EMA/H/C/005605/II/0004/G, Orphan**

Request for supplementary information adopted with a specific timetable.

Novartis Europharm Limited, Rapporteur: Janet Koenig, “Grouped application comprising two type II variations as follows:  
- Submission of the final reports from studies DMPK-R2200470 (REC). This is an in vitro evaluation of inducibility of OATP1V1, MDR1 and CYP3A4 by asciminib using human hepatocytes.  
- Submission of the final report from study DMPK-R2270399 (REC). This is a physiologically based PK modelling and simulations to characterize the effect of cyclodextrins on the exposure of asciminib.”  
Request for Supplementary Information adopted on 15.06.2023.

---

**Spinraza - nusinersen -  
EMA/H/C/004312/II/0029, Orphan**

Request for supplementary information adopted with a specific timetable.

Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, “Update of section 5.3 of the SmPC in order to update non-clinical information based

---



---

on final results from study P058-17-02. This is a 24-month carcinogenicity study when administered by subcutaneous injection in mouse.”

Request for Supplementary Information adopted on 22.06.2023.

---

**Synagis - palivizumab -  
EMA/H/C/000257/II/0132**

AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, “Update of sections 4.2 and 5.1 of the SmPC in order to update safety information based on results from safety data evaluations from multiple sources, including the clinical study W00-350, post-Marketing Clinical Surveillance Programme (REACH), literature searches and the AstraZeneca Global Patient Safety database.”

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

Request for supplementary information adopted with a specific timetable.

---

**TAGRISSO - osimertinib -  
EMA/H/C/004124/II/0050**

AstraZeneca AB, Rapporteur: Carolina Prieto Fernandez, “Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to modify the posology recommendations in the case of toxic epidermal necrolysis (TEN), add it as a new warning and add it to the list of adverse drug reactions (ADRs) with frequency uncommon and to update the frequency of interstitial lung disease (ILD) based on an internal safety information review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Opinion adopted on 22.06.2023.

Request for Supplementary Information adopted on 30.03.2023.

Positive Opinion adopted by consensus on 22.06.2023.

---

**Tecvayli - teclistamab -  
EMA/H/C/005865/II/0003**

Janssen-Cilag International N.V., Rapporteur: Johanna Lähteenvuo, “Update of sections 4.2, 4.6 and 5.2 of the SmPC in order to revise the dosing schedule, amend recommendations on contraception and breast-feeding and to update pharmacokinetic information, based on the latest data available; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local

Positive Opinion adopted by consensus on 22.06.2023.

---

representatives in the Package Leaflet.”  
Opinion adopted on 22.06.2023.  
Request for Supplementary Information adopted  
on 25.05.2023.

---

**TEPMETKO - tepotinib -  
EMA/H/C/005524/II/0005**

Positive Opinion adopted by consensus on  
15.06.2023.

Merck Europe B.V., Rapporteur: Filip Josephson,  
“Update of sections 4.5 and 5.2 of the SmPC in  
order to remove interactions with ‘CYP and P-gp  
inducers’ and ‘dual strong CYP3A and P-gp  
inhibitors, and P-gp inhibitors’ and to update  
pharmacokinetic information based on final  
results from the drug-drug interaction (DDI)  
studies MS200095-0051 and MS200095-0053.  
Study MS200095-0051 is a phase 1, open-label,  
single-sequence, cross-over study to evaluate  
the effect of multiple doses of carbamazepine on  
single-dose tepotinib pharmacokinetics in  
healthy participants, while study MS200095-  
0053 is a phase 1, open-label, single-sequence,  
cross-over study to evaluate the effect of  
multiple doses of itraconazole on single-dose  
tepotinib pharmacokinetics in healthy  
participants. The Package Leaflet is updated  
accordingly. In addition, the MAH took the  
opportunity to introduce minor changes to the  
PI.”

Opinion adopted on 15.06.2023.  
Request for Supplementary Information adopted  
on 09.02.2023.

---

**TUKYSA - tucatinib -  
EMA/H/C/005263/II/0013**

Request for supplementary information adopted  
with a specific timetable.

Seagen B.V., Rapporteur: Aaron Sosa Mejia,  
“Submission of the final report from study ONT-  
380-206 (HER2CLIMB) listed as a PAES in the  
Annex II of the Product Information. This is a  
phase 2 randomized, double-blinded, controlled  
study of tucatinib vs. placebo in combination  
with capecitabine and trastuzumab in patients  
with pretreated unresectable locally advanced or  
metastatic HER2+ breast carcinoma. The Annex  
II is updated accordingly.”

Request for Supplementary Information adopted  
on 22.06.2023.

---

**Vargatef - nintedanib -  
EMA/H/C/002569/II/0047/G**

Positive Opinion adopted by consensus on  
22.06.2023.

Boehringer Ingelheim International GmbH,  
Rapporteur: Aaron Sosa Mejia, “C.I.4: Update of  
section 5.2 of the SmPC in order to improve the

---

recommendation for the administration of nintedanib based on food compatibility data. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI.”

Opinion adopted on 22.06.2023.

Request for Supplementary Information adopted on 26.04.2023, 26.01.2023.

---

**Vokanamet - canagliflozin / metformin - EMEA/H/C/002656/II/0067/G**

Positive Opinion adopted by consensus on 15.06.2023.

Janssen-Cilag International N.V., Rapporteur: Martina Weise, “C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with lithium, based on a safety review. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

C.I.4: Update of section 4.8 of the SmPC in order to update the frequency for ‘vitamin B12 deficiency’ in the list of adverse drug reactions (ADRs) to ‘common’, based on a safety review. The Package Leaflet is updated accordingly.”

Opinion adopted on 15.06.2023.

Request for Supplementary Information adopted on 14.04.2023.

---

**Xultophy - insulin degludec / liraglutide - EMEA/H/C/002647/II/0049**

Positive Opinion adopted by consensus on 01.06.2023.

Novo Nordisk A/S, Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC in order to add dysgeusia to the list of adverse drug reactions (ADRs) with frequency uncommon based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 4.9 of the SmPC to update overdose information and to amend Annex A.”

Opinion adopted on 01.06.2023.

---

**Zokinvy - lonafarnib - EMEA/H/C/005271/II/0004, Orphan**

Request for supplementary information adopted with a specific timetable.

EigerBio Europe Limited, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2, 4.4, 4.5 and 6.6 of the SmPC in order to update drug-drug interaction information based on final results from Drug-Drug Interaction study EIG-LNF-021. This is a phase I, single-center, two period, single sequence, study to assess the effects of lonafarnib autoinhibition following multiple-dose lonafarnib and the effects of a

---

---

nonspecific CYP2C9 inhibitor on multiple-dose lonafarnib pharmacokinetics in healthy subjects. The Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 22.06.2023.

---

**WS2368**  
**Invokana-**  
**EMA/H/C/002649/WS2368/0061**  
**Vokanamet-**  
**EMA/H/C/002656/WS2368/0066**

Positive Opinion adopted by consensus on 15.06.2023.

Janssen-Cilag International N.V., Lead Rapporteur: Martina Weise, “To update section 4.4 of the SmPC in order amend an existing warning on the diabetic ketoacidosis, to indicate that glucosuria may persist longer than expected and that DKA may be prolonged after discontinuation of canagliflozin in some patients based on a cumulative review of literature, MAH global safety database, preclinical and clinical pharmacology data, and clinical study data including cases reports.” Opinion adopted on 15.06.2023. Request for Supplementary Information adopted on 12.05.2023, 08.12.2022.

---

**WS2407**  
**Efficib-EMA/H/C/000896/WS2407/0110**  
**Janumet-**  
**EMA/H/C/000861/WS2407/0109**  
**Ristfor-EMA/H/C/001235/WS2407/0098**  
**Velmetia-**  
**EMA/H/C/000862/WS2407/0115**

Positive Opinion adopted by consensus on 01.06.2023.

Merck Sharp & Dohme B.V., Lead Rapporteur: Johann Lodewijk Hillege, “To include significant changes to sections 4.4 and 4.8 of the SmPC and section 4 of the Package Leaflet for the medicinal products Janumet, Velmetia, Ristfor and Efficib, containing the active substances Metformin hydrochloride and Sitagliptin phosphate in order to include a warning for vitamin B12 deficiency and to change the frequency of vitamin B12 deficiency from very rare to common following the assessment of the medicinal product Glucophage, which also contains the active substance metformin, assessed as part of a mutual recognition procedure FR/H/0181/001-3. The same wording is used for the combination product. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to

---

---

update the list of local representatives in the Package Leaflet for Janumet, Ristfor and Efficib and to improve the wording in section 2 of the Package Leaflet.”

Opinion adopted on 01.06.2023.

Request for Supplementary Information adopted on 09.02.2023.

---

**WS2467**

**Adrovance-**

**EMA/H/C/000759/WS2467/0051**

**FOSAVANCE-**

**EMA/H/C/000619/WS2467/0054**

**VANTAVO-**

**EMA/H/C/001180/WS2467/0041**

Organon N.V., Lead Rapporteur: Christian Gartner, “Update of sections 4.4 and 4.8 the SmPC in order to include information on the risk of low-energy fractures in bones other than femur based on post-marketing case reports and the literature. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template and to introduce editorial changes.”

Request for Supplementary Information adopted on 15.06.2023.

Request for supplementary information adopted with a specific timetable.

---

**WS2489/G**

**Kinzalmono-**

**EMA/H/C/000211/WS2489/0119/G**

**Micardis-**

**EMA/H/C/000209/WS2489/0127/G**

**Pritor-**

**EMA/H/C/000210/WS2489/0132/G**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, “Grouped application consisting of:

C.I.4: Update of section 4.8 of the SmPC in order to include “hyponatremia” to the list of adverse drug reactions (ADRs) with frequency “rare”, based on post-marketing data and literature;

C.I.z (Type IB unforeseen): Update of section 4.2 of the SmPC to include the possibility of using the combination of telmisartan and amlodipine for lowering blood pressure, based on literature;

C.I.z (Type IB unforeseen): Update of section 4.7 of the SmPC to replace the terms “dizziness”

Request for supplementary information adopted with a specific timetable.

---

and "drowsiness" by "syncope" and "vertigo" to align with adverse reactions table in section 4.8 of SmPC.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, bring the PI in line with the latest QRD template version 10.3, and to implement editorial changes to the SmPC." Request for Supplementary Information adopted on 15.06.2023.

---

**WS2492**  
**Glyxambi-**  
**EMA/H/C/003833/WS2492/0052**

Positive Opinion adopted by consensus on 15.06.2023.

**Synjardy-**  
**EMA/H/C/003770/WS2492/0071**  
Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study PASS 1245-0137 listed as a category 3 study in the RMP. This is a multicentre international randomised parallel group double-blind placebo-controlled clinical trial of empagliflozin once daily to assess cardiorenal outcomes in patients with chronic kidney disease." Opinion adopted on 15.06.2023.

---

**B.5.3. CHMP-PRAC assessed procedures**

---

**Carbaglu - carglumic acid -**  
**EMA/H/C/000461/II/0045**

Positive Opinion adopted by consensus on 22.06.2023.

Recordati Rare Diseases, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to include a proposed dose adjustment for patients with impaired renal function based on final results from study RCD-P0-027; this is a Phase I, multicenter, open-label, parallel-group adaptive pharmacokinetic single dose study of oral Carbaglu in subjects with normal and varying degrees of impaired renal function. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in Annex II and Labelling, and to bring the PI in line with the latest QRD template version 10.3." Opinion adopted on 22.06.2023.

Request for Supplementary Information adopted

---

---

on 30.03.2023.

---

**Coagadex - human coagulation factor X -  
EMA/H/C/003855/II/0046, Orphan**

BPL Bioproducts Laboratory GmbH, Rapporteur:  
Daniela Philadelphly, PRAC Rapporteur: Menno  
van der Elst, "Submission of the final report  
from study TEN06 - NCT03161626 (REC  
EMA/H/C/003855). This is a non-  
interventional, multicentre, post-marketing  
registry study in three patients with moderate  
or severe hereditary FX deficiency, to assess  
Coagadex administered peri-operatively for  
haemostatic cover in major surgery during  
routine post-marketing use. The primary  
objective is to collect additional surgical data on  
the clinical effectiveness of Coagadex, in a post-  
marketing environment, for peri-operative  
haemostatic cover during major surgery in  
patients with moderate or severe hereditary  
factor X (FX) deficiency. The RMP version 3.0  
has also been submitted."

Opinion adopted on 08.06.2023.

Request for Supplementary Information adopted  
on 16.03.2023.

Positive Opinion adopted by consensus on  
08.06.2023.

---

**Enhertu - trastuzumab deruxtecan -  
EMA/H/C/005124/II/0031**

Daiichi Sankyo Europe GmbH, Rapporteur:  
Aaron Sosa Mejia, PRAC Rapporteur: Inês  
Ribeiro-Vaz, "Update of sections 4.8, 5.1 and  
5.2 of the SmPC in order to update safety,  
efficacy and pharmacokinetic information based  
on data from study DS8201-A-U301 and study  
DS8201-A-U302. Study U301 was a Phase 3,  
randomized, 2-arm, open-label, multicenter  
study designed to compare the safety and  
efficacy of T-DXd vs TPC in HER2-positive,  
unresectable and/or metastatic BC subjects who  
were resistant or refractory to T-DM1. Study  
U302 was a Phase 3, multicenter, randomized,  
open-label, 2-arm, active-controlled study in  
subjects with unresectable and/or metastatic  
HER2-positive (IHC 3+ or ISH-positive) BC  
previously treated with trastuzumab plus taxane  
in the advanced/metastatic setting or who had  
progressed within 6 months after neoadjuvant  
or adjuvant treatment involving a regimen  
including trastuzumab plus taxane. The Package  
Leaflet and Annex II are updated accordingly.  
The updated RMP version 4.1 has also been

Request for supplementary information adopted  
with a specific timetable.

---

submitted.”

Request for Supplementary Information adopted on 08.06.2023.

---

**Fluenz Tetra - influenza vaccine (live attenuated, nasal) -**

**EMA/H/C/002617/II/0130**

AstraZeneca AB, Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné,

“Submission of the final report from study MA-VA-MEDI3250-1116 (A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2 to 17 Years of Age) listed as a category 3 study in the RMP. This was an observational study.

The objective of this study was to evaluate the effectiveness of Q/LAIV compared to IIV or no vaccine in community-dwelling subjects 2 to 17 years of age against laboratory-confirmed influenza. The RMP version 11.0 has also been submitted.”

Opinion adopted on 08.06.2023.

Positive Opinion adopted by consensus on 08.06.2023.

---

**GAVRETO - pralsetinib -**

**EMA/H/C/005413/II/0010**

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information in the treatment of adult patients with RET fusion-positive advanced NSCLC based on final results (NSCLC indication) from study ARROW/BO42863, a Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU 667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumours listed as a specific obligation in the Annex II.

The RMP version 1.5 has also been submitted.”

Opinion adopted on 22.06.2023.

Request for Supplementary Information adopted on 25.05.2023, 23.02.2023.

Positive Opinion adopted by consensus on 22.06.2023.

---

**GAVRETO - pralsetinib -**

**EMA/H/C/005413/II/0012**

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2, 4.4 and 4.5 of the SmPC in order to amend posology recommendations, warnings and drug-drug interaction information regarding the co-administration with CYP3A4 inhibitors, P-gp

Request for supplementary information adopted with a specific timetable.



---

inhibitors and CYP3A4 inducers based on final results from the DDI study GP43162, listed as a category 3 study in the RMP, as well as results from the physiologically based pharmacokinetic (PBPK) analyses summarised in the PBPK Report 1120689. Study GP43162 is a phase 1, open-label, fixed-sequence study to evaluate the effect of a single dose of cyclosporine on the single dose pharmacokinetics of pralsetinib in healthy subjects. The RMP version 1.6 has also been submitted.”

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

---

**GIVLAARI - givosiran - EMEA/H/C/004775/II/0011/G, Orphan**  
Alnylam Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, “Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-007 listed as a category 3 study in the RMP; This is a 104-week Subcutaneous Injection Carcinogenicity Study in Sprague Dawley Rats. Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-004; This is a 26-week Subcutaneous Injection Carcinogenicity Study in TgRasH2 Mice. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Opinion adopted on 08.06.2023.

Request for Supplementary Information adopted on 14.04.2023, 12.01.2023, 29.09.2022.

Positive Opinion adopted by consensus on 08.06.2023.

---

**Imnovid - pomalidomide - EMEA/H/C/002682/II/0047, Orphan**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Monica Martinez Redondo, “Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational

Positive Opinion adopted by consensus on 08.06.2023.

---

materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The updated RMP version 16 was provided.”

Opinion adopted on 08.06.2023.

Request for Supplementary Information adopted on 14.04.2023, 09.02.2023, 27.10.2022.

---

**Piqray - alpelisib -  
EMA/H/C/004804/II/0018**

Novartis Europharm Limited, Rapporteur:  
Carolina Prieto Fernandez, PRAC Rapporteur:  
Menno van der Elst, “Update of sections 4.5 and 5.2 of the SmPC in order to update drug-drug interaction information, based on final results from study BYL719A2111; this is a phase 1, open-label, fixed-sequence, two-period drug-drug interaction (DDI) study evaluating the PK probe substrates for CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 when administered either alone or in combination with repeated doses of alpelisib. The Annex II and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Request for Supplementary Information adopted on 22.06.2023, 16.03.2023.

---

Request for supplementary information adopted with a specific timetable.

**Revlimid - lenalidomide -  
EMA/H/C/000717/II/0123**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The

---

Positive Opinion adopted by consensus on 08.06.2023.

---

updated RMP version 38.2 was provided.”  
Opinion adopted on 08.06.2023.  
Request for Supplementary Information adopted  
on 14.04.2023, 09.02.2023, 27.10.2022.

---

**Simponi - golimumab -  
EMA/H/C/000992/II/0109**

Positive Opinion adopted by consensus on  
22.06.2023.

Janssen Biologics B.V., Rapporteur: Kristina  
Dunder, PRAC Rapporteur: Mari Thorn, “Update  
of the Package Leaflet in order to update the  
Instructions for Use (IFU) for the pre-filled pen.”  
Opinion adopted on 22.06.2023.  
Request for Supplementary Information adopted  
on 26.04.2023, 26.01.2023.

---

**Thalidomide BMS - thalidomide -  
EMA/H/C/000823/II/0076**

Positive Opinion adopted by consensus on  
08.06.2023.

Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Tiphaine  
Vaillant, “Update of section 4.4 of the SmPC,  
Annex IID and Article 127a and the  
tools/documents included in the Educational  
Healthcare Professional Kit, in order to  
harmonise the terminology utilised in the RMP  
and PI documents relating to the safety concern  
of teratogenicity and its risk minimisation  
measure of the Pregnancy Prevention Plan  
across the 3 IMiDs. These proposed changes will  
only have a limited impact on the National  
Competent Authority (NCA)-approved  
content/text of the educational materials, and  
the key messages to the HCP and patients.  
Furthermore, the regulatory obligations  
regarding the PPP will not be impacted. The  
MAH is also taking the opportunity to update the  
RMP with PASS Protocol milestones, and to  
make some editorial changes in the labelling.  
The updated RMP version 20 was provided.”  
Opinion adopted on 08.06.2023.  
Request for Supplementary Information adopted  
on 14.04.2023, 09.02.2023, 27.10.2022.

---

**Vabysmo - faricimab -  
EMA/H/C/005642/II/0002**

Positive Opinion adopted by consensus on  
22.06.2023.

Roche Registration GmbH, Rapporteur: Jayne  
Crowe, PRAC Rapporteur: Inês Ribeiro-Vaz,  
“Update of sections 4.2, 4.4, 4.8 and 5.1 of the  
SmPC in order to update efficacy and safety  
information and to update the warnings and the  
list of adverse drug reactions (ADRs), based on  
longer-term results from studies GR40306  
(TENAYA) and GR40844 (LUCERNE); these are

---

---

phase 3, multicenter, randomized, double-masked, active comparator-controlled, 112-week studies to evaluate the efficacy and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD); the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”  
Opinion adopted on 22.06.2023.  
Request for Supplementary Information adopted on 23.02.2023.

---

**Veklury - remdesivir -  
EMA/H/C/005622/II/0046**

Positive Opinion adopted by consensus on 22.06.2023.

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, “Update of sections 4.6 and 5.2 of the SmPC in order to update information on pregnancy and breastfeeding based on final results from study IMPAACT 2032 listed as a category 3 study in the RMP; this is a Phase 4, prospective, open-label, non-randomised study to address PK and safety of remdesivir in pregnant women. In addition, the MAH provided post-marketing pregnancy data and literature to support this variation. The Package Leaflet is updated accordingly. The RMP version 7.0 is acceptable.”  
Opinion adopted on 22.06.2023.  
Request for Supplementary Information adopted on 16.03.2023.

---

**Veklury - remdesivir -  
EMA/H/C/005622/II/0050**

Request for supplementary information adopted with a specific timetable.

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, “Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to address the safety of remdesivir and its metabolites in patients with hepatic impairment and to update information on hepatic and coagulation laboratory abnormalities based on final results from study GS US 540 9014: “A phase 1 open-label, adaptive, single-dose study to evaluate the pharmacokinetics of remdesivir and its metabolite(s) in subjects with normal hepatic function and hepatic impairment”, listed as a category 3 study in the RMP, and on safety data from post-marketing and clinical trials experience.  
The Package Leaflet is updated accordingly. The RMP version 5.4 has also been submitted. In

---

---

addition, the MAH took the opportunity to submit Minor Linguistic Amendments (MLA) for Veklury.”  
Request for Supplementary Information adopted on 22.06.2023.

---

**XOSPATA - gilteritinib - EMEA/H/C/004752/II/0013, Orphan**  
Astellas Pharma Europe B.V., Rapporteur: Ingrid Wang, PRAC Rapporteur: Martin Huber, “Update of sections 4.2 and 5.2 in order to update the information on renal impairment based on final results from study 2215-CL-0114, listed as a category 3 study in the RMP. Study 2215-CL-0114 is a phase 1, single-dose, open-label study to investigate the effect of renal impairment on gilteritinib pharmacokinetics, safety and tolerability in 9 participants with severe renal impairment compared to 8 participants with normal renal function.  
The RMP version 4.0 has also been submitted.  
In addition, the MAH took the opportunity to introduce editorial changes.”  
Request for Supplementary Information adopted on 22.06.2023.

Request for supplementary information adopted with a specific timetable.

---

#### **B.5.4. PRAC assessed procedures**

---

PRAC Led  
**Aldurazyme - laronidase - EMEA/H/C/000477/II/0085**  
Sanofi B.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, “To update section 4.2 of the SmPC in order to modify the administration instructions following the assessment of procedure PSUSA/00001830/202104 based on literature review.  
The Package Leaflet is updated accordingly. The RMP version 1.0 has also been submitted.”  
Request for Supplementary Information adopted on 08.06.2023, 09.02.2023.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led  
**CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0033**  
Ipsen Pharma, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of the final report from study F-FR-60000-001 (CASSIOPE) listed as a category 3 study in the RMP. This is a

Request for supplementary information adopted with a specific timetable.

---

prospective, non-imposed and non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy. The RMP version 7.0 has also been submitted.”

Request for Supplementary Information adopted on 08.06.2023.

---

PRAC Led

**Eurartesim - piperazine tetraphosphate / arteminol - EMEA/H/C/001199/II/0040/G**

Alfasigma S.p.A., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “C.I.13: Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) listed as a category 3 study in the RMP. This is a European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented.

C.I.11.b: Submission of an updated RMP version 16.1 in order to delete “Severe Malaria” from the Missing Information.”

Request for Supplementary Information adopted on 08.06.2023.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**EXJADE - deferasirox - EMEA/H/C/000670/II/0085**

Novartis Europharm Limited, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, “Submission of an updated RMP version 21.0 in order to include the physician survey CICL670A2429 as a PASS category 3, based on the submission of a draft version of the protocol for the physician survey CICL670A2429. The Annex IID is updated to remove one sentence related to ‘surveillance programme’ and to introduce a minor correction.”

Request for Supplementary Information adopted on 08.06.2023.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**Fintepla - fenfluramine - EMEA/H/C/003933/II/0017, Orphan**

UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Submission of an updated RMP version 2.10 in order to implement a targeted follow-up questionnaire

Request for supplementary information adopted with a specific timetable.

---

(FUQ) to further improve the collection of follow-up information on cases of vascular heart disease (VHD) and pulmonary arterial hypertension (PAH) suggested by PRAC following the assessment of procedure EMEA/H/C/PSUSA/00010907/202112.” Request for Supplementary Information adopted on 08.06.2023, 14.04.2023, 12.01.2023.

---

PRAC Led  
**JCOVDEN - COVID-19 vaccine Janssen (Ad26.COV2.S) - EMEA/H/C/005737/II/0071/G**  
Janssen-Cilag International N.V., PRAC  
Rapporteur: Ulla Wändel Liminga, PRAC-CHMP  
liaison: Kristina Dunder, “Grouped application consisting of:  
1) Submission of the final study report of a clinical TTS characterisation study listed as a category 3 study in the RMP. This is a Test Pre- and Post-Vaccination Serum Across All Populations Using Clinical Samples From Ad26-based Company Vaccine Studies Other Than Ad26.COV2.S;  
2) Submission of the Addendum to final CSR of the study VAC31518COV2001 listed as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 2a study to evaluate a range of dose levels and vaccination intervals of Ad26.COV2.S in healthy adults aged 18 to 55 years, and adults aged 65 years and older. The RMP version 7.1 is submitted and updated accordingly. In addition, the MAH updated the milestones of several studies.”  
Opinion adopted on 08.06.2023.

---

Positive Opinion adopted by consensus on 08.06.2023.

PRAC Led  
**Nexium Control - esomeprazole - EMEA/H/C/002618/II/0038**  
GlaxoSmithKline Dungarvan Ltd, PRAC  
Rapporteur: Rugile Pilviniene, PRAC-CHMP  
liaison: Vilma Petrikaite, “Submission of an updated RMP version 2.0 in order to update the list of safety concerns to meet the definition of important risk and missing information provided in GVP Module V Rev. 2”  
Request for Supplementary Information adopted on 08.06.2023.

---

Request for supplementary information adopted with a specific timetable.

PRAC Led  
**Olumiant - baricitinib -**

---

Positive Opinion adopted by consensus on

---

<p><b>EMA/H/C/004085/II/0039/G</b></p> <p>Eli Lilly Nederland B.V., PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final reports from studies I4V-MC-B016 and I4V-MC-B011 (in terms of Objective 4 for RA cohort) listed as category 3 non-interventional PASS studies in the RMP. B016 is a drug utilisation study for the assessment of off-label use of baricitinib in the paediatric population in the United Kingdom. B011 is a retrospective cohort study to assess the safety of baricitinib compared with other therapies used in the treatment of rheumatoid arthritis in Nordic countries. The RMP version 19.1 has also been submitted."</p> <p>Opinion adopted on 08.06.2023.</p>	<p>08.06.2023.</p>
<p>PRAC Led</p> <p><b>Ozurdex - dexamethasone - EMA/H/C/001140/II/0044</b></p> <p>AbbVie Deutschland GmbH &amp; Co. KG, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of an updated Annex II and RMP version 11 in order to remove additional risk minimisation measure: Patient guide, audio CD (where required)."</p> <p>Request for Supplementary Information adopted on 08.06.2023, 16.03.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p><b>Pradaxa - dabigatran etexilate - EMA/H/C/000829/II/0144</b></p> <p>Boehringer Ingelheim International GmbH, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of the final report from the Human Factors Study (007-HFE-009035), listed as a category 3 study in the RMP; this is a non-interventional study to assess the effectiveness of a training video to mitigate potential medication errors during the reconstitution and dosing of the dabigatran etexilate paediatric oral solution."</p> <p>Opinion adopted on 08.06.2023.</p>	<p>Positive Opinion adopted by consensus on 08.06.2023.</p>
<p>PRAC Led</p> <p><b>Revlimid - lenalidomide - EMA/H/C/000717/II/0126</b></p> <p>Bristol-Myers Squibb Pharma EEIG, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the</p>	<p>Request for supplementary information adopted with a specific timetable.</p>



---

final report from study CC-5013-MDS-010 listed as an obligation in the Annex II of the Product Information. This is a prospective non-interventional post-authorisation safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q). Section D of the Annex II and the RMP (version 39) are updated accordingly.”

Request for Supplementary Information adopted on 08.06.2023.

---

PRAC Led

**Sialanar - glycopyrronium -  
EMA/H/C/003883/II/0026**

Proveca Pharma Limited, PRAC Rapporteur: Zane Neikena, PRAC-CHMP liaison: Elita Poplavska, “Submission of an updated RMP version 3.1 in order to remove a Drug Utilisation Study (DUS). In addition, the safety concerns, pharmacovigilance activities and risk minimisation measures in the RMP of Sialanar are revised to be in line with the Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 2). Furthermore, Annex II D “Conditions or restrictions with regard to the safe and effective use of the medicinal product” was revised to delete information about the utilisation study from the key elements of the physician educational material.”

Opinion adopted on 08.06.2023.

Request for Supplementary Information adopted on 12.05.2023, 16.03.2023, 12.01.2023.

Positive Opinion adopted by consensus on 08.06.2023.

---

PRAC Led

**Vaxzevria - COVID 19 vaccine (ChAdOx1 S  
[recombinant]) -  
EMA/H/C/005675/II/0091**

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, “Submission of the final report from study D8111R00020 listed as a category 3 study in the RMP. This is a systematic literature review of observational studies evaluating safety after vaccination with Vaxzevria in patients taking immunosuppressant medications and/or with primary immunodeficiency.”

Opinion adopted on 08.06.2023.

Positive Opinion adopted by consensus on 08.06.2023.

---

<p>PRAC Led <b>WS2483</b> <b>Lixiana-EMEA/H/C/002629/WS2483/0045</b> <b>Roteas-EMEA/H/C/004339/WS2483/0032</b> Daiichi Sankyo Europe GmbH, Lead PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from DSE-EDO-04-14-EU (Non- Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients with Non- Valvular Atrial Fibrillation, ETNA-AF Europe), listed as a category 3 study in the RMP (MEA 006). This is a multicentre, prospective, non- interventional, observational PASS. The RMP version 15.1 has also been submitted." Opinion adopted on 08.06.2023.</p>	<p>Positive Opinion adopted by consensus on 08.06.2023.</p>
---	---

---

<p>PRAC Led <b>WS2487</b> <b>Humalog-</b> <b>EMEA/H/C/000088/WS2487/0199</b> <b>Liprolog-</b> <b>EMEA/H/C/000393/WS2487/0159</b> Eli Lilly Nederland B.V., Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "To remove severe hypoglycemia as a result of incorrect or incomplete data provided to a compatible software application which is listed as an important potential risk for the Tempo Pen and all associated risk minimisation measures, following PRAC assessment of F3Z- MC-B030 PASS protocol (EMA/PRAC/781358/2022, 29 September 2022)." Opinion adopted on 22.06.2023.</p>	<p>Positive Opinion adopted by consensus on 22.06.2023.</p>
--	---

---

#### **B.5.5. CHMP-CAT assessed procedures**

---

<p><b>Abecma - idcabtagene vicleucel -</b> <b>EMEA/H/C/004662/II/0032/G, Orphan,</b> <b>ATMP</b> Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang Opinion adopted on 22.06.2023, 16.06.2023. Request for Supplementary Information adopted on 17.05.2023.</p>	<p>Positive Opinion adopted by consensus on 22.06.2023.</p>
--	---

---

<p><b>Abecma - idcabtagene vicleucel -</b> <b>EMEA/H/C/004662/II/0034, Orphan,</b> <b>ATMP</b> Bristol-Myers Squibb Pharma EEIG, Rapporteur:</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
--	---

---

---

Rune Kjekken, CHMP Coordinator: Ingrid Wang  
Request for Supplementary Information adopted  
on 16.06.2023.

---

**Breyanzi - lisocabtagene maraleucel /  
lisocabtagene maraleucel -  
EMA/H/C/004731/II/0013/G, ATMP**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Concetta Quintarelli, CHMP Coordinator:  
Armando Genazzani  
Opinion adopted on 22.06.2023, 16.06.2023.  
Request for Supplementary Information adopted  
on 17.02.2023.

Positive Opinion adopted by consensus on  
22.06.2023.

---

**Breyanzi - lisocabtagene maraleucel /  
lisocabtagene maraleucel -  
EMA/H/C/004731/II/0018/G, ATMP**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Concetta Quintarelli, CHMP Coordinator:  
Armando Genazzani

Request for supplementary information adopted  
with a specific timetable.

---

**Breyanzi - lisocabtagene maraleucel /  
lisocabtagene maraleucel -  
EMA/H/C/004731/II/0019, ATMP**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Concetta Quintarelli, CHMP Coordinator:  
Armando Genazzani  
Request for Supplementary Information adopted  
on 16.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**CARVYKTI - ciltacabtagene autoleucel -  
EMA/H/C/005095/II/0016, Orphan,  
ATMP**  
Janssen-Cilag International NV, Rapporteur: Jan  
Mueller-Berghaus, CHMP Coordinator: Jan  
Mueller-Berghaus,  
Opinion adopted on 22.06.2023, 16.06.2023.

Positive Opinion adopted by consensus on  
22.06.2023.

---

**Imlygic - talimogene laherparepvec -  
EMA/H/C/002771/II/0062/G, ATMP**  
Amgen Europe B.V., Rapporteur: Maija  
Tarkkanen, CHMP Coordinator: Johanna  
Lähteenvuo  
Opinion adopted on 22.06.2023, 16.06.2023.  
Request for Supplementary Information adopted  
on 17.05.2023.

Positive Opinion adopted by consensus on  
22.06.2023.

---

**Kymriah - tisagenlecleucel -  
EMA/H/C/004090/II/0069, Orphan,  
ATMP**  
Novartis Europharm Limited, Rapporteur: Rune  
Kjekken, CHMP Coordinator: Ingrid Wang  
Request for Supplementary Information adopted

Request for supplementary information adopted  
with a specific timetable.

---

on 15.06.2023, 17.05.2023.

---

**Kymriah - tisagenlecleucel -  
EMA/H/C/004090/II/0070/G, Orphan,  
ATMP**

Novartis Europharm Limited, Rapporteur: Rune  
Kjeken, CHMP Coordinator: Ingrid Wang  
Opinion adopted on 22.06.2023, 16.06.2023.

Positive Opinion adopted by consensus on  
22.06.2023.

---

**Libmeldy - atidarsagene autotemcel -  
EMA/H/C/005321/II/0015, Orphan,  
ATMP**

Orchard Therapeutics (Netherlands) B.V.,  
Rapporteur: Carla Herberts, CHMP Coordinator:  
Johann Lodewijk Hillege  
Request for Supplementary Information adopted  
on 16.06.2023.

Request for supplementary information adopted  
with a specific timetable.

---

**B.5.6. CHMP-PRAC-CAT assessed procedures**

**B.5.7. PRAC assessed ATMP procedures**

**B.5.8. Unclassified procedures and worksharing procedures of type I variations**

---

**WS2399/G  
Mirapexin-  
EMA/H/C/000134/WS2399/0104/G  
Sifrol-**

**EMA/H/C/000133/WS2399/0095/G**  
Boehringer Ingelheim International GmbH, Lead  
Rapporteur: Thalia Marie Estrup Blicher  
Opinion adopted on 08.06.2023.  
Request for Supplementary Information adopted  
on 30.03.2023, 19.01.2023.

Positive Opinion adopted by consensus on  
08.06.2023.

---

**WS2412  
Hexacima-  
EMA/H/C/002702/WS2412/0144  
Hexyon-  
EMA/H/C/002796/WS2412/0148**

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-  
Berghaus  
Opinion adopted on 01.06.2023.  
Request for Supplementary Information adopted  
on 30.03.2023.

Positive Opinion adopted by consensus on  
01.06.2023.

---

**WS2427/G  
Silodosin Recordati-  
EMA/H/C/004964/WS2427/0011/G  
Silodyx-  
EMA/H/C/001209/WS2427/0051/G**

Request for supplementary information adopted  
with a specific timetable.

---

**Urorec-****EMA/H/C/001092/WS2427/0054/G**

Recordati Ireland Ltd, Generic, Generic of Urorec, Lead Rapporteur: Margareta Bego  
Request for Supplementary Information adopted on 08.06.2023.

---

**WS2445****Ambirix-****EMA/H/C/000426/WS2445/0127****Cervarix-****EMA/H/C/000721/WS2445/0122****Fendrix-****EMA/H/C/000550/WS2445/0082****Infanrix hexa-****EMA/H/C/000296/WS2445/0329****Synflorix-****EMA/H/C/000973/WS2445/0180****Twinrix Adult-****EMA/H/C/000112/WS2445/0162****Twinrix Paediatric-****EMA/H/C/000129/WS2445/0163**

GlaxoSmithkline Biologicals SA, Lead Rapporteur: Kristina Dunder  
Opinion adopted on 15.06.2023.

---

Positive Opinion adopted by consensus on 15.06.2023.

**WS2456/G****Infanrix hexa-****EMA/H/C/000296/WS2456/0328/G**

GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke  
Opinion adopted on 01.06.2023.

---

Positive Opinion adopted by consensus on 01.06.2023.

**WS2458****Juluca-EMA/H/C/004427/WS2458/0051****Tivicay-EMA/H/C/002753/WS2458/0087****Triumeq-****EMA/H/C/002754/WS2458/0112**

ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig  
Opinion adopted on 01.06.2023.

---

Positive Opinion adopted by consensus on 01.06.2023.

**WS2464****Aerius-EMA/H/C/000313/WS2464/0105****Azomyr-****EMA/H/C/000310/WS2464/0109****Neoclarityn-****EMA/H/C/000314/WS2464/0103**

Organon N.V., Duplicate, Duplicate of Allex (SRD), Azomyr, Opulis (SRD), Lead Rapporteur: Christophe Focke, "C.I.7.a - To delete the pharmaceutical form orodispersible tablets from

---

Positive Opinion adopted by consensus on 08.06.2023.

---

the marketing authorisation of:  
- Aerius from EU/1/00/160/037 up to and including EU/1/00/160/060  
- Azomyr from EU/1/00/157/035 up to and including EU/1/00/157/058  
- Neoclarityn from EU/1/00/161/035 up to and including EU/1/00/161/058”  
Opinion adopted on 08.06.2023.

---

<b>WS2466</b> <b>Fluenz Tetra-</b> <b>EMA/H/C/002617/WS2466/0128</b> <b>Pandemic influenza vaccine H5N1</b> <b>AstraZeneca-</b> <b>EMA/H/C/003963/WS2466/0063</b> AstraZeneca AB, Lead Rapporteur: Christophe Focke Opinion adopted on 01.06.2023.	Positive Opinion adopted by consensus on 01.06.2023.
---	--

---

<b>WS2468/G</b> <b>Hexacima-</b> <b>EMA/H/C/002702/WS2468/0148/G</b> <b>Hexyon-</b> <b>EMA/H/C/002796/WS2468/0152/G</b> Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.06.2023.	Positive Opinion adopted by consensus on 22.06.2023.
--	--

---

<b>WS2469</b> <b>Hexacima-</b> <b>EMA/H/C/002702/WS2469/0147</b> <b>Hexyon-</b> <b>EMA/H/C/002796/WS2469/0151</b> <b>MenQuadfi-</b> <b>EMA/H/C/005084/WS2469/0023</b> Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 15.06.2023.	Positive Opinion adopted by consensus on 15.06.2023.
---	--

---

<b>WS2472</b> <b>Afinitor-</b> <b>EMA/H/C/001038/WS2472/0085</b> <b>Votubia-</b> <b>EMA/H/C/002311/WS2472/0081</b> Novartis Europharm Limited, Lead Rapporteur: Janet Koenig Opinion adopted on 01.06.2023.	Positive Opinion adopted by consensus on 01.06.2023.
---	--

---

<b>WS2473</b> <b>ProQuad-</b> <b>EMA/H/C/000622/WS2473/0161</b> <b>Zostavax-</b>	Positive Opinion adopted by consensus on 15.06.2023.
---	--

---

---

**EMA/H/C/000674/WS2473/0146**

Merck Sharp & Dohme B.V., Lead Rapporteur:

Jan Mueller-Berghaus,

Opinion adopted on 15.06.2023.

---

**WS2484**

**Filgrastim Hexal-**

**EMA/H/C/000918/WS2484/0071**

**Zarzio-EMA/H/C/000917/WS2484/0072**

Sandoz GmbH, Lead Rapporteur: Johann

Lodewijk Hillege

Request for Supplementary Information adopted

on 22.06.2023.

---

Request for supplementary information adopted with a specific timetable.

---

**B.5.9. Information on withdrawn type II variation / WS procedure**

---

**EVUSHELD - tixagevimab / cilgavimab -**

**EMA/H/C/005788/II/0003**

AstraZeneca AB, Rapporteur: Jan Mueller-

Berghaus, PRAC Rapporteur: Kimmo Jaakkola,

"Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of

the SmPC in order to change the posology

recommendations in the pre-exposure

prophylaxis indication based on study TACKLE

(D8851C00001).

The Package Leaflet is updated accordingly. The

RMP version 2 has also been submitted."

Request for Supplementary Information adopted

on 13.10.2022.

---

The MAH withdrew the procedure on 07.06.2022.

---

**B.5.10. Information on type II variation / WS procedure with revised timetable**

---

**Eptifibatide Accord - eptifibatide -**

**EMA/H/C/004104/II/0015/G**

Accord Healthcare S.L.U., Generic, Generic of

Integrilin, Rapporteur: Jayne Crowe

Request for Supplementary Information adopted

on 12.05.2023.

---

Request by the applicant for an extension to the clock stop to respond to the RSI adopted in May 2023.

The CHMP agreed to the request for an extension to the clock stop to respond to the RSI adopted in May 2023.

---

---

**B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION**

---

**B.6.1. Start of procedure for New Applications: timetables for information**

---

**liquid ethanolic extract 30 per cent (w/w)**

**of allium cepa fresh bulb and citrus limon**

**fresh fruit / dry aqueous extract of**

**paullinia cupana seed / dry hydroethanolic**

**extract of theobroma cacao seed -**

**EMA/H/C/004155**

---

---

treatment of alopecia areata in children and adolescents

---

**fruquintinib - EMEA/H/C/005979**

treatment of metastatic colorectal cancer

---

**meningococcal group a, b, c, w and y vaccine - EMEA/H/C/006165**

indicated for active immunisation to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y

---

**ustekinumab - EMEA/H/C/005918**

treatment of adult patients with moderately to severely active Crohn's disease and active ulcerative colitis.

---

**B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information**

---

**AMGEVITA - adalimumab - EMEA/H/C/004212/X/0036/G**

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, "Extension application to introduce a new strength, 80 mg [0.8 ml (100 mg/ml)] solution for injection, grouped with quality variations The RMP (version 6.0) is updated in accordance."

---

**Menveo - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/X/0119**

GSK Vaccines S.r.l, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "Extension application to introduce a new pharmaceutical form (solution for injection). The RMP (version 11.0) is updated in accordance."

---

**Vyepti - eptinezumab - EMEA/H/C/005287/X/0011**

H. Lundbeck A/S, Rapporteur: Jan Mueller-Berghaus, "Line extension application to add a new strength (300 mg concentrate for solution for infusion)."

---

**XALKORI - crizotinib - EMEA/H/C/002489/X/0080/G**

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Extension application to introduce a new pharmaceutical form (granules in capsules for

---



---

opening) associated with new strengths (20, 50 and 150 mg), grouped with a type II variation (C.I.6.a) to include the treatment of paediatric patients with relapsed or refractory, systemic ALK-positive ALCL or unresectable, recurrent, or refractory ALK-positive IMT to change the lower end of the age range from  $\geq 6$  years to  $\geq 1$  year for Xalkori following the assessment of II/0072 based on final results from study ADVL0912. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted.”

---

### **B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information**

### **B.6.4. Annual Re-assessments: timetables for adoption**

---

#### **EVKEEZA - evinacumab -**

**EMA/H/C/005449/S/0010**

Ultragenyx Germany GmbH, Rapporteur:  
Johann Lodewijk Hillege, Co-Rapporteur: Alar  
Irs, PRAC Rapporteur: Mari Thorn

---

### **B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed**

---

#### **AJOVY - fremanezumab -**

**EMA/H/C/004833/R/0044**

TEVA GmbH, Rapporteur: Jan Mueller-Berghaus,  
Co-Rapporteur: Johann Lodewijk Hillege, PRAC  
Rapporteur: Kirsti Villikka

---

#### **GHRVELIN - macimorelin -**

**EMA/H/C/004660/R/0020**

Consilient Health Limited, Rapporteur: Martina  
Weise, Co-Rapporteur: Jean-Michel Race (FR),  
PRAC Rapporteur: Liana Gross-Martirosyan

---

#### **Idacio - adalimumab -**

**EMA/H/C/004475/R/0022**

Fresenius Kabi Deutschland GmbH, Rapporteur:  
Johann Lodewijk Hillege, Co-Rapporteur: Vilma  
Petrikaite, PRAC Rapporteur: Mari Thorn

---

#### **Miglustat Dipharma - miglustat -**

**EMA/H/C/004904/R/0019**

DIPHARMA Arzneimittel GmbH, Generic, Generic  
of Zavesca, Rapporteur: Frantisek Drafi, PRAC

---

---

Rapporteur: Mari Thorn

---

**Mulpleo - lusutrombopag -  
EMA/H/C/004720/R/0018**

Shionogi B.V., Rapporteur: Daniela Philadelphy,  
Co-Rapporteur: Ewa Balkowiec Iskra, PRAC  
Rapporteur: Mari Thorn

---

**Rizmoic - naldemedine -  
EMA/H/C/004256/R/0023**

Shionogi B.V., Rapporteur: Thalia Marie Estrup  
Blicher, Co-Rapporteur: Christophe Focke, PRAC  
Rapporteur: Rhea Fitzgerald

---

**Skyrizi - risankizumab -  
EMA/H/C/004759/R/0039**

AbbVie Deutschland GmbH & Co. KG,  
Rapporteur: Finbarr Leacy, PRAC Rapporteur:  
Liana Gross-Martirosyan

---

**Zirabev - bevacizumab -  
EMA/H/C/004697/R/0029**

Pfizer Europe MA EEIG, Rapporteur: Eva  
Skovlund, Co-Rapporteur: Alexandre Moreau,  
PRAC Rapporteur: Anette Kirstine Stark

---

#### **B.6.6. VARIATIONS – START OF THE PROCEDURE**

**Timetables for adoption** provided that the validation has been completed.

#### **B.6.7. Type II Variations scope of the Variations: Extension of indication**

---

**CARVYKTI - ciltacabtagene autoleucel -  
EMA/H/C/005095/II/0021, Orphan,  
ATMP**

Janssen-Cilag International NV, Rapporteur: Jan  
Mueller-Berghaus, CHMP Coordinator: Jan  
Mueller-Berghaus, PRAC Rapporteur: Jo Robays,  
"Extension of indication to include treatment of  
adult patients with relapsed and refractory  
multiple myeloma, who have received at least 1  
prior therapy, including an IMiD and a PI, have  
demonstrated disease progression on or after  
the last therapy and are refractory to  
lenalidomide for CARVYKTI, based on interim  
results from study MMY3002 listed as a specific  
obligation (SOB/006) in the Annex II. This is an  
ongoing, Phase 3, randomized, open-label,  
multicentre study to determine whether  
treatment with cilta-cel provides an efficacy  
benefit compared to standard therapy in  
participants with relapsed and lenalidomide-  
refractory multiple myeloma. As a consequence,

---

---

sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI. As part of the application the MAH is requesting a 1-year extension of the market protection.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**CellCept - mycophenolate mofetil -  
EMA/H/C/000082/II/0170/G**

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, “C.I.6.a: Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly.

Type IB (C.I.z): To update section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other three CellCept formulations. And for alignment with the current QRD guidance, the Package Leaflet was updated to cross reference section 2 in section 6 for sodium content.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3.”

---

**Cibinqo - abrocitinib -  
EMA/H/C/005452/II/0010**

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, “Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis for CIBINQO based on final results from non-clinical study 00655292 [21GR211] and interim results from clinical study B7451015; this is a Phase III multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications,

---

---

administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted.”

---

**EVKEEZA - evinacumab -  
EMA/H/C/005449/II/0011**

Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Mari Thorn, “Extension of indication to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia (HoFH) aged 5 years and older for EVKEEZA, based on interim results from study R1500-CL-17100, as well as supportive information from an updated interim analysis of study R1500-CL-1719, and an extrapolation analysis (including population PK, population PK/PD, and simulation analyses). R1500-CL-17100 is an ongoing multicentre, three-part, single-arm, open-label study evaluating the efficacy, safety, and tolerability of evinacumab in paediatric patients aged  $\geq 5$  to 11 years with HoFH. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to introduce minor editorial changes to the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.3.”

---

**Fexinidazole Winthrop - fexinidazole -  
EMA/H/W/002320/II/0016**

Sanofi Winthrop Industrie, Rapporteur: Fátima Ventura, PRAC Rapporteur: Liana Gross-Martirosyan, “Extension of indication to include treatment of both first stage (haemo-lymphatic) and second stage (meningo-encephalitic) of human African trypanosomiasis (HAT) due to *Trypanosoma brucei rhodesiense* for FEXINIDAZOLE WINTHROP based final results from study DNDI-FEX-07-HAT - Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to *Trypanosoma brucei rhodesiense*: a multicentre, open-label clinical trial; this is a phase-II/III, multicenter, open-label, non-randomized,

---

---

single-arm clinical trial to assess the efficacy and safety of fexinidazole in patients with r-HAT. The primary objective of study DNDi-FEX-07-HAT, for which the final results are presented in this application, is: To show that the fatality rate (r HAT or treatment related death) at EOH in stage-2 patients treated with fexinidazole is smaller than a threshold of unacceptable rate of 8.5%. It is noteworthy that the primary objective of study DNDi-FEX-07-HAT is related to a safety parameter. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted.”

---

**Keytruda - pembrolizumab -  
EMA/H/C/003820/II/0138**

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, “Extension of indication to include KEYTRUDA in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a Phase 3 randomized, double blind study of Pembrolizumab plus Gemcitabine/Cisplatin versus Placebo plus Gemcitabine/Cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 43.1 of the RMP has also been submitted.”

---

**VeraSeal - human fibrinogen / human  
thrombin - EMA/H/C/004446/II/0027**

Instituto Grifols, S.A., Rapporteur: Daniela Philadelphia, Co-Rapporteur: Ewa Balkowicz Iskra, PRAC Rapporteur: Amelia Cupelli, “Extension of indication to include treatment of children for VeraSeal, based on final results from study IG1405; this is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of VeraSeal as an adjunct to haemostasis during surgery in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of

---

---

the RMP has also been submitted.”

---

**B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects**

---

**COMIRNATY - COVID-19 mRNA vaccine  
(nucleoside-modified) -**

**EMA/H/C/005735/II/0182/G**

BioNTech Manufacturing GmbH, Rapporteur:

Filip Josephson

---

**B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

**B.6.10. CHMP-PRAC assessed procedures**

**B.6.11. PRAC assessed procedures**

**B.6.12. CHMP-CAT assessed procedures**

---

**Abecma - idecabtagene vicleucel -**

**EMA/H/C/004662/II/0037/G, Orphan,  
ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:

Rune Kjekken, CHMP Coordinator: Ingrid Wang

---

**B.6.13. CHMP-PRAC-CAT assessed procedures**

**B.6.14. PRAC assessed ATMP procedures**

**B.6.15. Unclassified procedures and worksharing procedures of type I variations**

**B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

**B.7.1. Yearly Line listing for Type I and II variations**

**B.7.2. Monthly Line listing for Type I variations**

**B.7.3. Opinion on Marketing Authorisation transfer (MMD only)**

**B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)**

**B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)**

**B.7.6. Notifications of Type I Variations (MMD only)**

**C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)**

**D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)**

**E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

## **E.1. PMF Certification Dossiers:**

### **E.1.1. Annual Update**

### **E.1.2. Variations:**

### **E.1.3. Initial PMF Certification:**

## **E.2. Time Tables – starting & ongoing procedures: For information**

---

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

---

## **F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver**

### **F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended**

### **F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health**

## **G. ANNEX G**

### **G.1. Final Scientific Advice (Reports and Scientific Advice letters):**

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### **G.2. PRIME**

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

#### **G.2.1. List of procedures concluding at 19-22 June 2023 CHMP plenary**

---

##### ***Cardiovascular Diseases***

---

Treatment of Primary Aldosteronism

The CHMP denied eligibility to PRIME and adopted the critical summary report.

---

#### **G.2.2. List of procedures starting in June 2023 for July 2023 CHMP adoption of outcomes**

## **H. ANNEX H - Product Shared Mailboxes – e-mail address**